[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 217
1. Chen D, Kennedy A, Wang JY, Zeng W, Zhao Q, Pearl M, Zhang M, Suo Z, Nesland JM, Qiao Y, Ng AK, Hirashima N, Yamane T, Mori Y, Mitsumata M, Ghersi G, Chen WT: Activation of EDTA-resistant gelatinases in malignant human tumors. Cancer Res; 2006 Oct 15;66(20):9977-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In malignant human tumors, seprase is expressed predominantly in tumor cells as shown by in situ hybridization and immunohistochemistry.
  • Seprase expression and activation occur most prevalently in ovarian carcinoma but were also detected in four other malignant tumor types, including adenocarcinoma of the colon and stomach, invasive ductal carcinoma of the breast, and malignant melanoma.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Disodium EDTA .
  • Hazardous Substances Data Bank. ETHYLENEDIAMINE TETRAACETIC ACID .
  • Hazardous Substances Data Bank. DISODIUM CALCIUM EDTA .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2004 Oct 1;306(5693):108-11 [15459390.001]
  • [Cites] J Biol Chem. 2004 Aug 13;279(33):34691-7 [15175333.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5657-61 [7911242.001]
  • [Cites] Int J Cancer. 1994 Aug 1;58(3):385-92 [7519584.001]
  • [Cites] Am J Pathol. 1995 May;146(5):1150-60 [7747809.001]
  • [Cites] J Biol Chem. 1997 Mar 21;272(12):7595-601 [9065413.001]
  • [Cites] Biochim Biophys Acta. 1997 Jul 10;1361(1):11-9 [9247085.001]
  • [Cites] Eur J Biochem. 1998 Jun 15;254(3):650-4 [9688278.001]
  • [Cites] Mod Pathol. 1998 Sep;11(9):855-63 [9758365.001]
  • [Cites] Hepatology. 1999 Jun;29(6):1768-78 [10347120.001]
  • [Cites] J Biol Chem. 1999 Aug 27;274(35):24947-52 [10455171.001]
  • [Cites] Oncology. 2004;67(5-6):411-9 [15713998.001]
  • [Cites] Mol Cancer Ther. 2005 Mar;4(3):351-60 [15767544.001]
  • [Cites] J Biol Chem. 2005 May 20;280(20):19441-4 [15809306.001]
  • [Cites] Cancer Lett. 2005 Sep 28;227(2):229-36 [16196122.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5702-10 [7923219.001]
  • [Cites] J Biol Chem. 1999 Dec 17;274(51):36505-12 [10593948.001]
  • [Cites] J Biol Chem. 2000 Jan 28;275(4):2554-9 [10644713.001]
  • [Cites] Int J Cancer. 2001 Jan 20;95(1):67-72 [11241314.001]
  • [Cites] J Biol Chem. 2002 Aug 9;277(32):29231-41 [12023964.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4767-72 [12183436.001]
  • [Cites] J Biol Chem. 1998 May 22;273(21):13366 [12755100.001]
  • [Cites] Anticancer Res. 2003 Jul-Aug;23(4):3195-8 [12926053.001]
  • [Cites] Oncology. 2003;65(4):363-70 [14707457.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2712-6 [15087384.001]
  • [Cites] Oncogene. 2004 Jul 15;23(32):5435-46 [15133496.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(21):8296-300 [2172980.001]
  • (PMID = 17047060.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA039077; United States / NIBIB NIH HHS / EB / R01EB002065; United States / NIBIB NIH HHS / EB / R01 EB002065; United States / NCRR NIH HHS / RR / M01 RR010710; United States / NCRR NIH HHS / RR / M01RR10710; United States / NCI NIH HHS / CA / R01CA0039077
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Recombinant Proteins; 9G34HU7RV0 / Edetic Acid; EC 3.4.14.- / Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / fibroblast activation protein alpha; EC 3.4.24.- / Gelatinases
  • [Other-IDs] NLM/ NIHMS11890; NLM/ PMC1626657
  •  go-up   go-down


2. Powell RD, Pettay JD, Powell WC, Roche PC, Grogan TM, Hainfeld JF, Tubbs RR: Metallographic in situ hybridization. Hum Pathol; 2007 Aug;38(8):1145-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metallographic in situ hybridization.
  • Metallographic methods, in which a target is visualized using a probe or antibody that deposits metal selectively at its binding site, offers many advantages for bright-field in situ hybridization (ISH) detection as well as for other labeling and detection methods.
  • Enzyme metallography, a novel procedure in which an enzymatic probe is used to deposit metal directly from solution, has been used to develop bright-field ISH methods for HER2 gene determination in breast cancer and other biopsy specimens.
  • [MeSH-major] Gold Colloid / chemistry. In Situ Hybridization / methods. Nucleic Acids / chemistry. Silver Compounds / chemistry. Silver Staining / methods
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Breast Neoplasms / chemistry. Breast Neoplasms / diagnosis. Breast Neoplasms / genetics. Enzymes / chemistry. Female. Humans. Receptor, ErbB-2 / analysis. Receptor, ErbB-2 / genetics

  • Hazardous Substances Data Bank. SILVER COMPOUNDS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640553.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R43CA111182-01; United States / NCI NIH HHS / CA / 5R42CA83618-03; United States / NIGMS NIH HHS / GM / 5R44 GM064257-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzymes; 0 / Gold Colloid; 0 / Nucleic Acids; 0 / Silver Compounds; EC 2.7.10.1 / Receptor, ErbB-2
  • [Number-of-references] 125
  •  go-up   go-down


3. Bouché O, Penault-Llorca F: [HER2 and gastric cancer: a novel therapeutic target for trastuzumab]. Bull Cancer; 2010 Dec;97(12):1429-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HER2 protein overexpression by immunohistochemistry (IHC) and/or erB2 gene amplification by in situ hybridization (ISH) was detected in 4-28% of gastric or gastro-oesophageal junction (GOJ) cancers.
  • Trastuzumab is a humanized monoclonal antibody directed against HER2 with known efficacy in patients with HER2+ early or metastatic breast cancer.
  • Trastuzumab plus FP chemotherapy has become the standard treatment for patients with HER2+ non-pretreated metastatic adenocarcinoma of the stomach or GOJ cancer.
  • The standardized immunohistochemical scoring system differs from that recommended for breast cancer given the heterogeneity of HER2 expression and the frequency of incomplete membranous staining in gastric cancers.
  • Equivocal IHC2+ tumours should be tested by ISH with two tools: fluorescence in situ hybridization (FISH) or bright field in situ hybridization (SISH).
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Capecitabine. Cisplatin / administration & dosage. Cisplatin / contraindications. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Immunohistochemistry / methods. In Situ Hybridization / methods. Paraffin Embedding. Randomized Controlled Trials as Topic. Trastuzumab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21134821.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


Advertisement
4. Charpin C, Secq V, Giusiano S, Carpentier S, Andrac L, Lavaut MN, Allasia C, Bonnier P, Garcia S: A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays. Int J Cancer; 2009 May 1;124(9):2124-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays.
  • Quantitative immunocytochemical assays of 1,200 breast carcinomas were assessed after construction of tissue microarrays.
  • Quantitative densitometric measurement of immunoprecipitates by computer-assisted devices from digitized microscopic images allows standardized high-throughput "in situ" molecular profiling within tumors.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism


5. Istvanic S, Fischer AH, Banner BF, Eaton DM, Larkin AC, Khan A: Cell blocks of breast FNAs frequently allow diagnosis of invasion or histological classification of proliferative changes. Diagn Cytopathol; 2007 May;35(5):263-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell blocks of breast FNAs frequently allow diagnosis of invasion or histological classification of proliferative changes.
  • Two major limitations of breast fine needle aspiration (FNA) compared with core needle biopsies (CNB) are the inability to determine whether a cancer is invasive and to classify proliferative lesions.
  • We studied 40 consecutive "rapid cell blocks" from breast FNAs with surgical pathology follow-up to test whether cell blocks can overcome these limitations.
  • Cell blocks from 12 of 14 benign breast FNAs showed sufficient cells to assign a histologic diagnosis of no hyperplasia (1 case, confirmed on follow-up) and usual hyperplasia (11 cases; confirmed in eight of 11 on follow-up).
  • Specific histologic diagnoses included intraductal papilloma (2 cases), and in situ lobular neoplasia (2 cases).
  • Cell blocks complement smears and monolayers and appear to overcome major limitations of breast FNA.
  • [MeSH-major] Biopsy, Fine-Needle. Breast / pathology. Breast Neoplasms / pathology. Neoplasms, Ductal, Lobular, and Medullary / pathology. Paraffin Embedding / methods
  • [MeSH-minor] Adenocarcinoma / classification. Adenocarcinoma / pathology. Carcinoma in Situ / classification. Carcinoma in Situ / pathology. Carcinoma, Lobular / classification. Carcinoma, Lobular / pathology. Cell Proliferation. Female. Humans. Hyperplasia. Neoplasm Invasiveness. Papilloma, Intraductal / classification. Papilloma, Intraductal / pathology. Phyllodes Tumor / classification. Phyllodes Tumor / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17427225.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Banerjee S, Dhar G, Haque I, Kambhampati S, Mehta S, Sengupta K, Tawfik O, Phillips TA, Banerjee SK: CCN5/WISP-2 expression in breast adenocarcinoma is associated with less frequent progression of the disease and suppresses the invasive phenotypes of tumor cells. Cancer Res; 2008 Sep 15;68(18):7606-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CCN5/WISP-2 expression in breast adenocarcinoma is associated with less frequent progression of the disease and suppresses the invasive phenotypes of tumor cells.
  • Although previous in vitro studies predicted that CCN5/WISP-2 may act as an anti-invasive gene in breast cancer, the distribution pattern of CCN5 in breast cancer samples is conflicting.
  • Thus, we systematically investigated the CCN5 expression profile in noninvasive and invasive breast tumor samples and its functional relevance in breast cancer progression.
  • The studies showed that CCN5 expression is biphasic, such that in normal samples CCN5 expression is undetectable, whereas its expression is markedly increased in noninvasive breast lesions, including atypical ductal hyperplasia and ductal carcinoma in situ.
  • Therefore, our data suggest a protective function of CCN5 in noninvasive breast tumor cells.
  • This hypothesis was further supported by our in vitro studies illuminating that CCN5 is a negative regulator of migration and invasion of breast cancer cells, and these events could be regulated by CCN5 through the modulation of the expression of genes essential for an invasive front.
  • Collectively, these studies suggest that the protective effect of CCN5 in breast cancer progression may have important therapeutic implications.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Intercellular Signaling Peptides and Proteins / biosynthesis. Transcription Factors / biosynthesis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794149.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 1 P20 RR15563
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCN Intercellular Signaling Proteins; 0 / Cadherins; 0 / Intercellular Signaling Peptides and Proteins; 0 / RNA, Messenger; 0 / Repressor Proteins; 0 / Transcription Factors; 0 / WISP2 protein, human; 0 / snail family transcription factors; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


7. Persons DL, Tubbs RR, Cooley LD, Dewald GW, Dowling PK, Du E, Mascarello JT, Rao KW, Wilson KS, Wolff DJ, Habegger-Vance G: HER-2 fluorescence in situ hybridization: results from the survey program of the College of American Pathologists. Arch Pathol Lab Med; 2006 Mar;130(3):325-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER-2 fluorescence in situ hybridization: results from the survey program of the College of American Pathologists.
  • CONTEXT: Fluorescence in situ hybridization (FISH) is a common method used to determine HER-2 status in breast cancer.
  • DESIGN: During the past 5 years, unstained sections from 9 invasive breast carcinomas were used for HER-2 FISH proficiency testing, allowing for comparison of FISH results among a large number of laboratories.
  • Reproducibility of test results among laboratories was excellent for breast tumors with low copy number (no HER-2 amplification) and for breast tumors with high copy number (HER-2 amplification).
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. Cytogenetic Analysis / standards. In Situ Hybridization / standards. Receptor, ErbB-2 / genetics. Societies, Medical

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16519559.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


8. Sauer T, Beraki K, Noren T, Garred O, Naess O: EGFR gene copy number heterogeneity in fine-needle aspiration cytology from breast carcinomas determined by chromogenic in situ hybridization. Diagn Cytopathol; 2005 Oct;33(4):228-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR gene copy number heterogeneity in fine-needle aspiration cytology from breast carcinomas determined by chromogenic in situ hybridization.
  • Most studies have shown epidermal growth factor receptor (EGFR) overexpression to be associated with poor prognostic factors in breast carcinomas.
  • The aim of our study was to investigate the heterogeneity of the EGFR gene copy number in breast carcinomas.
  • The material consisted of air-dried smears from 29 breast carcinomas and 3 breast cancer cell lines (MCF-7, SKBR3, and T47D).
  • Chromogenic in situ hybridization (CISH) was done using chromogenic detection.
  • There was no relationship between IHC protein expression of EGFR and EGFR gene copy number or EGFR gene/CEP7 ratio.In conclusion, most breast carcinomas had a balanced EGFR gene/CEP7 copy number with a mean ratio of 1.04.
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. Gene Dosage. In Situ Hybridization / methods. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 16138375.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromogenic Compounds; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


9. Frenkel M, Mishra BM, Sen S, Yang P, Pawlus A, Vence L, Leblanc A, Cohen L, Banerji P, Banerji P: Cytotoxic effects of ultra-diluted remedies on breast cancer cells. Int J Oncol; 2010 Feb;36(2):395-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic effects of ultra-diluted remedies on breast cancer cells.
  • We conducted an in vitro study to determine if products prescribed by a clinic in India have any effect on breast cancer cell lines.
  • We studied four ultra-diluted remedies (Carcinosin, Phytolacca, Conium and Thuja) against two human breast adenocarcinoma cell lines (MCF-7 and MDA-MB-231) and a cell line derived from immortalized normal human mammary epithelial cells (HMLE).
  • The remedies exerted preferential cytotoxic effects against the two breast cancer cell lines, causing cell cycle delay/arrest and apoptosis.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Breast Neoplasms / drug therapy. Homeopathy / methods. Phytotherapy / methods
  • [MeSH-minor] Apoptosis / drug effects. Blotting, Western. Cell Cycle / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Separation. Cell Survival / drug effects. Chromatography, High Pressure Liquid. Conium / chemistry. Female. Flow Cytometry. Gene Expression / drug effects. Humans. In Situ Hybridization, Fluorescence. India. Phytolacca / chemistry. Telomere / drug effects. Thuja / chemistry


10. Koyama T: [The point of mammography]. Nihon Hoshasen Gijutsu Gakkai Zasshi; 2005 Oct 20;61(10):1392-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Breast Neoplasms / radiography. Mammography / methods
  • [MeSH-minor] Adenocarcinoma / radiography. Carcinoma in Situ / radiography. Carcinoma, Ductal, Breast / radiography. Humans. Magnetic Resonance Imaging

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270015.001).
  • [ISSN] 0369-4305
  • [Journal-full-title] Nihon Hōshasen Gijutsu Gakkai zasshi
  • [ISO-abbreviation] Nihon Hoshasen Gijutsu Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Wang Y, Zhang D, Zheng W, Luo J, Bai Y, Lu Z: Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray. Cancer; 2008 Mar 15;112(6):1325-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Methylation frequencies in the tumor samples were detected in 18% of samples for the breast cancer 1 gene BRCA1, in 43% of samples for the tissue inhibitor of metalloproteinase 3 gene TIMP-3, in 38% of samples for the cyclin-dependent kinase inhibitor 4A gene p16INK4a, in 54% of samples for the cadherin 13 gene CDH13, in 50% of samples for the death-associated protein kinase gene DAPK, in 11% of samples for the E-cadherin gene ECAD, in 25% of samples for the insulin-like growth factor binding protein 7 gene IGFBP7, in 18% of samples for the Ras association domain family 1 gene RASSF1, in 68% of samples for the adenomatous polyposis coli gene APC, in 7% of samples for the cyclin-dependent kinase inhibitor gene p15, in 18% of samples for the CD44 cell adhesion molecule gene, in 29% of samples for the human Mut-L homolog gene hMLH, in 32% of samples for the human telomerase reverse transcriptase gene hTERT, in 64% of samples for the calcitonin gene-related polypeptide alpha gene CALCA, and in 54% of samples for the estrogen receptor gene ER; however, methylation was not observed in the majority of corresponding nonmalignant tissues.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / secondary. Apoptosis Regulatory Proteins / genetics. Cadherins / genetics. Calcium-Calmodulin-Dependent Protein Kinases / genetics. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / secondary. Case-Control Studies. CpG Islands. Cyclin-Dependent Kinase Inhibitor p15 / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Death-Associated Protein Kinases. Female. Humans. In Situ Hybridization. Insulin-Like Growth Factor Binding Proteins / genetics. Lung / metabolism. Lung / pathology. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Tissue Inhibitor of Metalloproteinase-3 / genetics. Ubiquitin-Protein Ligases / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 American Cancer Society.
  • (PMID = 18286531.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / CDH17 protein, human; 0 / Cadherins; 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / H-cadherin; 0 / Insulin-Like Growth Factor Binding Proteins; 0 / RNA, Messenger; 0 / TIMP3 protein, human; 0 / Tissue Inhibitor of Metalloproteinase-3; 0 / insulin-like growth factor binding protein-related protein 1; EC 2.7.11.1 / Death-Associated Protein Kinases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases; EC 6.3.2.- / BRAP protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


12. Plevova P, Cerna D, Balcar A, Foretova L, Zapletalova J, Silhanova E, Curik R, Dvorackova J: CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer. Neoplasma; 2010;57(4):325-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer.
  • Breast cancer associated with BRCA1 and BRCA2 gene mutations differs from non-BRCA tumors in several respects.
  • Of 40 breast cancer samples examined, 15 and 9 were from BRCA1 and BRCA2 mutation carriers, respectively, and 16 from patients without mutation.
  • Fluorescence in situ hybridization showed that eight tumors exhibited CCND1 amplification (20%; 3 BRCA1, 3 BRCA2, 2 non-BRCA).
  • [MeSH-major] BRCA1 Protein / genetics. BRCA2 Protein / genetics. Breast Neoplasms / genetics. Cyclin D1 / genetics. Gene Amplification. Germ-Line Mutation / genetics. Trans-Activators / genetics
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adult. Apoptosis Regulatory Proteins. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / genetics. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Female. Genetic Predisposition to Disease. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Middle Aged. Prognosis. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Young Adult


13. Matei M, Azoicăi D: [Histopathological characteristics of genital and breast cancer included in epidemiologic study cohort]. Rev Med Chir Soc Med Nat Iasi; 2009 Apr-Jun;113(2):540-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Histopathological characteristics of genital and breast cancer included in epidemiologic study cohort].
  • The correct management of genitals and breast cancers and the improving of the preventional and therapeutical successes ratio involve the knowledge of the histopathological features of these nosological entities which have different origins, different risk factors, different simptomatology and also different prognosis.
  • AIM: The descriptive evaluation of the histopathological features of the genitals and breast cancers to women from North-Eastern region of Romania.
  • MATERIAL AND METHOD: We have been included in the study 96 women (age range 23-77 years, mean 54,49) diagnosed with breast cancer, ovarian cancer, endometrial cancer and cervical cancer at the hospital admission, residency in the Obstetrics and Gynecology Clinics within 23 months.
  • The following main parameters were assessed: histological types, stage at diagnosis, Pap test.
  • RESULTS: The following cases' repartition on diagnostic types was observed: breast cancer (44 cases), cervical cancer (24 cases), endometrial cancer (16 cases) and ovarian cancer (12 cases).
  • In our study, the most affected range of age was 40-69 years for breast cancer, 30-59 years for cervical cancer, over 6 years for endometrial cancer and 50-59 years for ovarian cancer.
  • For the cervical neoplasia, 40% of analyzed cases were in incipient stages (in situ to IB stage lessions).
  • More than 50% of breast cancer cases have been diagnosed in advances stages (IIB to IIIC stages).
  • For the endometrium carcinoma, 45% of cases have been identified in incipient stages (in situ to IC).
  • CONCLUSION: From a histopathological point of view, for cervical neoplasia, squamous carcinoma was the most frequent type (87%), for breast neoplasia--invasive ductal carcinoma (80%) and for ovary and endometrium malignant tumors--adenocarcinoma (69%, respectively 83%).
  • [MeSH-major] Breast Neoplasms / epidemiology. Breast Neoplasms / pathology. Genital Neoplasms, Female / epidemiology. Genital Neoplasms, Female / pathology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Ductal, Breast / epidemiology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Cohort Studies. Endometrial Neoplasms / epidemiology. Endometrial Neoplasms / pathology. Female. Humans. Incidence. Middle Aged. Neoplasm Staging. Ovarian Neoplasms / epidemiology. Ovarian Neoplasms / pathology. Prognosis. Risk Factors. Romania / epidemiology. Uterine Neoplasms / epidemiology. Uterine Neoplasms / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21495363.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


14. Otsuki Y, Yamada M, Shimizu S, Suwa K, Yoshida M, Tanioka F, Ogawa H, Nasuno H, Serizawa A, Kobayashi H: Solid-papillary carcinoma of the breast: clinicopathological study of 20 cases. Pathol Int; 2007 Jul;57(7):421-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid-papillary carcinoma of the breast: clinicopathological study of 20 cases.
  • The purpose of the present paper was to evaluate the clinicopathological and biological features of 20 Japanese patients with solid-papillary carcinoma of the breast (SPC) or SPC associated with invasive breast cancer.
  • The incidence of SPC among all the breast cancers treated at two institutions was 1.1% and 1.7%, respectively.
  • When all the cases were classified and analyzed according to both the 2002 tumor node metastasis (TNM) classification system and the Nottingham histological grade, SPC patients, even those with invasive cancers, seemed to have longer disease-free survival compared to patients with the other invasive breast cancers of matching grade and stage.
  • Clinicopathologically, SPC could be regarded as a separate type of ductal carcinoma in situ.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / chemistry. Adenocarcinoma, Mucinous / classification. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma, Neuroendocrine / chemistry. Carcinoma, Neuroendocrine / classification. Carcinoma, Neuroendocrine / pathology. Carcinoma, Neuroendocrine / surgery. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasms, Multiple Primary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17587241.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


15. Alex G: Apocrine adenocarcinoma of the nipple: a case report. Cases J; 2008;1(1):88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine adenocarcinoma of the nipple: a case report.
  • Apocrine carcinoma of the nipple is extremely rare and this case to the author's knowledge is only the third reported case worldwide and the first with associated ductal carcinoma in situ elsewhere in the breast.
  • A seventy one year old caucasian female presented to the breast clinic with a growth on her nipple which proved on histopathological analysis to be an apocrine carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatol Online J. 2008;14(6):5 [18713586.001]
  • [Cites] Acta Chir Belg. 2004 Aug;104(4):476-8 [15469170.001]
  • [Cites] Breast. 2005 Feb;14(1):3-10 [15695074.001]
  • [Cites] J Neurooncol. 2006 May;77(3):285-9 [16314948.001]
  • (PMID = 18700029.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2526981
  •  go-up   go-down


16. Horiguchi S, Hishima T, Hayashi Y, Shiozawa Y, Horiguchi K, Kuroi K, Toi M, Funata N, Eishi Y: HER-2/neu cytoplasmic staining is correlated with neuroendocrine differentiation in breast carcinoma. J Med Dent Sci; 2010 Jun;57(2):155-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER-2/neu cytoplasmic staining is correlated with neuroendocrine differentiation in breast carcinoma.
  • HER2 oncoprotein plays an essential role in breast cancer growth and differentiation.
  • In the present study, we investigated the subcellular localization of HER2 protein in 1053 primary breast cancer tissues.
  • None of the 34 specimens showed amplification of the HER2 protein by fluorescence in situ hybridization.
  • Although the result is preliminary, it warrants further study on the role of the cytoplasmic variant form of HER2 in breast cancer growth, particularly in the aspect of neuroendocrine differentiation.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Neuroendocrine Cells / pathology. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD56 / analysis. Carcinoma, Lobular / chemistry. Carcinoma, Lobular / pathology. Cell Differentiation. Chromogranin A / analysis. Coloring Agents. Cytoplasm / chemistry. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Middle Aged. Phosphopyruvate Hydratase / analysis. Synaptophysin / analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21073134.001).
  • [ISSN] 1342-8810
  • [Journal-full-title] Journal of medical and dental sciences
  • [ISO-abbreviation] J. Med. Dent. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Chromogranin A; 0 / Coloring Agents; 0 / Synaptophysin; EC 2.7.10.1 / Receptor, ErbB-2; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


17. Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, Chen B: EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol; 2005 Aug;18(8):1027-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations.
  • The human epidermal growth factor receptor (HER) family of receptor tyrosine kinase has been extensively studied in breast cancer; however, systematic studies of EGFR gene amplification and protein overexpression in breast carcinoma are lacking.
  • We studied EGFR gene amplification by chromogenic in situ hybridization (CISH) and protein expression by immunohistochemistry in 175 breast carcinomas, using tissue microarrays.
  • HER-2 gene amplification by fluorescence in situ hybridization (FISH) and protein overexpression by immunohistochemistry were also studied.
  • The EGFR mRNA level, based on Affymetrix U133 chip hybridization data, was increased relative to other breast cancer samples in three of the five tumors showing gene amplification.
  • Approximately 6% of breast carcinomas show EGFR amplification with EGFR protein overexpression and may be candidates for trials of EGFR-targeted antibodies or small inhibitory molecules.
  • [MeSH-major] Breast Neoplasms / pathology. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. DNA Mutational Analysis / methods. Female. Gene Amplification. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization / methods. In Situ Hybridization, Fluorescence. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Middle Aged. Mutation. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptor, ErbB-2 / genetics. Tissue Array Analysis


18. Tot T: The origins of early breast carcinoma. Semin Diagn Pathol; 2010 Feb;27(1):62-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The origins of early breast carcinoma.
  • Assessing the distribution of the in situ and invasive components of breast carcinomas and the extent of the disease represent an integrated part of our diagnostic routine.
  • In this article, we summarize findings from 792 consecutive breast carcinoma cases, each documented in large-format histology slides.
  • Of these, 35.0% (42/120) of the purely in situ carcinomas were diffuse and occupied mostly larger ducts, whereas 37.5% (45/120) were multifocal and involved several distant terminal ductal-lobular units (TDLUs).
  • The proportion of unifocal in situ cases involving a single TDLU or several neighboring TDLUs was 27.5% (33/120).
  • Forty-one percent (136/332) of early (< 15 mm) invasive carcinomas and 40.0% (136/340) of larger invasive tumors contained only a single invasive focus, with or without an in situ component within it.
  • The remaining tumors were nonunifocal because of multiple invasive or multiple in situ foci or both.
  • The proportion of extensive nonunifocal cases within purely in situ, early invasive, and more advanced invasive cases were 45.0% (54/120), 42.5% (141/332), and 42.4% (144/340), respectively.
  • Breast carcinoma seems to develop within a field of genetic alterations, often at multiple sites, and a considerable proportion of the cases comprise extensive lesions occupying a tissue space > or = 40 mm in all tumor size categories.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20306831.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Kajiwara H, Kumaki N, Hirabayashi K, Miyazawa M, Nakamura N, Hirasawa T, Muramatsu T, Mikami M, Yasuda M, Osamura RY: A case of oncocytic carcinoma of the endometrium. Arch Gynecol Obstet; 2009 May;279(5):733-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report an unusual case of endometrial adenocarcinoma in a 80-year-old woman who underwent mastectomy for breast cancer at 68 years of age.
  • Components of the carcinoma were focally observed in situ.
  • Distinguishing between primary uterine neoplasm and carcinoma caused by metastasis of breast cancer appears important.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Neoplasms, Second Primary / pathology

  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18795309.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


20. McLaren BK, Gobbi H, Schuyler PA, Olson SJ, Parl FF, Dupont WD, Page DL: Immunohistochemical expression of estrogen receptor in enlarged lobular units with columnar alteration in benign breast biopsies: a nested case-control study. Am J Surg Pathol; 2005 Jan;29(1):105-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of estrogen receptor in enlarged lobular units with columnar alteration in benign breast biopsies: a nested case-control study.
  • The prognostic and therapeutic implications of estrogen receptor (ER) status in breast cancer are well known.
  • Whether ER status plays a role in benign breast lesions and the progression to malignancy has not been proven.
  • Enlarged lobular units with columnar alteration (ELUCA), also known as unfolded lobular units, have been associated with mild elevations in subsequent breast cancer risk.
  • We examined the association of ERalpha expression in ELUCA with invasive breast cancer risk.
  • A nested case-control study was performed of women with ELUCA who had undergone benign breast surgery.
  • Eighty-two women who developed invasive breast cancer on follow-up were matched by age and year of biopsy with 166 women who did not develop invasive breast cancer.
  • Relative risks of breast cancer were estimated by odds ratios derived from conditional logistic regression analyses.
  • The relative risk of invasive breast cancer in women with ERalpha-negative ELUCA was 1.85 times that of women with ERalpha-positive lesions (95% confidence interval, 1.0-3.4, P=0.04).
  • These findings have implications for risk assessment in benign breast biopsies and are of particular interest given the controversy currently surrounding hormone replacement therapy.
  • [MeSH-major] Adenocarcinoma / metabolism. Breast / metabolism. Breast Neoplasms / metabolism. Carcinoma in Situ / metabolism. Precancerous Conditions / metabolism. Receptors, Estrogen / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15613861.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen
  •  go-up   go-down


21. Huemer GM, Schrenk P, Moser F, Wagner E, Wayand W: Oncoplastic techniques allow breast-conserving treatment in centrally located breast cancers. Plast Reconstr Surg; 2007 Aug;120(2):390-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncoplastic techniques allow breast-conserving treatment in centrally located breast cancers.
  • BACKGROUND: Operative techniques for oncoplastic reconstruction combine oncologic extirpation of the tumor with immediate reconstruction of breast shape and symmetry.
  • These techniques are increasingly being used for breast-conservation therapy of centrally located breast carcinomas.
  • The goal of this study was to provide an overview of the various surgical options for oncoplastic treatment of central breast carcinomas.
  • METHODS: From September of 1998 through January of 2005, 31 women (median age, 61 years) were treated for 32 centrally located breast carcinomas by breast-conserving therapy.
  • There were 27 invasive tumors (median size, 13.5 mm), and five patients had ductal carcinoma in situ (median size, 39.6 mm).
  • Two patients required a secondary mastectomy because of ductal carcinoma in situ with positive surgical margins in the final histology.
  • In a median follow-up of 33.8 months, there were no local recurrences in the remaining breast or axilla, but two patients developed distant metastases.
  • CONCLUSIONS: Breast carcinoma of small size that occurs in a central location can be safely treated oncologically by breast conservation therapy.
  • [MeSH-major] Breast Neoplasms / surgery. Mastectomy, Segmental / methods
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / surgery. Carcinoma, Lobular / pathology. Carcinoma, Lobular / surgery. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17632339.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Kunju LP, Ding Y, Kleer CG: Tubular carcinoma and grade 1 (well-differentiated) invasive ductal carcinoma: comparison of flat epithelial atypia and other intra-epithelial lesions. Pathol Int; 2008 Oct;58(10):620-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of 14 TC, eight (57%) had associated FEA, seven (50%) had micropapillary atypical ductal hyperplasia (ADH), three (21%) had low nuclear grade ductal carcinoma in situ (DCIS), and four (29%) had lobular neoplasia.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Carcinoma, Intraductal, Noninfiltrating / metabolism. Cell Nucleus / metabolism. Cell Nucleus / pathology. Epithelial Cells / pathology. Female. Humans. In Situ Hybridization, Fluorescence. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Prognosis. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18801081.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA107469; United States / NCI NIH HHS / CA / CA090876; United States / NCI NIH HHS / CA / CA107469
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


23. Ousingsawat J, Spitzner M, Puntheeranurak S, Terracciano L, Tornillo L, Bubendorf L, Kunzelmann K, Schreiber R: Expression of voltage-gated potassium channels in human and mouse colonic carcinoma. Clin Cancer Res; 2007 Feb 1;13(3):824-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Voltage-gated Kv potassium channels, like ether a go-go (EAG) channels, have been recognized for their oncogenic potential in breast cancer and other malignant tumors.
  • Genomic amplification of Eag-1 was found in 3.4% of all human colorectal adenocarcinoma and was an independent marker of adverse prognosis.
  • [MeSH-minor] Aged. Animals. Breast Neoplasms. Colon / metabolism. Diverticulitis / metabolism. Epithelial Cells / metabolism. Ether-A-Go-Go Potassium Channels / metabolism. Female. Humans. In Situ Hybridization, Fluorescence. Inflammation. Male. Mice. Mice, Inbred C57BL


24. Lissoni P, Messina G, Rovelli F, Brivio F, Fumagalli L, Villa S, Bartolacelli E: HER2 expression in breast cancer: correlation with endocrine function and psychological status in operable and metastatic breast cancer. In Vivo; 2009 Nov-Dec;23(6):987-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER2 expression in breast cancer: correlation with endocrine function and psychological status in operable and metastatic breast cancer.
  • BACKGROUND: Node involvement, negative estrogen receptor (ER) and HER2 expression are the main negative prognostic factors for breast cancer.
  • Prolactin (PRL) is involved in the control of breast cancer growth and differentiation.
  • Surgery-induced hyperprolactinemia seems to be a positive prognostic factor for operable breast cancer, whereas high PRL levels may predict a poor prognosis in women with metastatic breast cancer.
  • In this study, we evaluated the relation between HER2 expression and PRL blood concentrations in women with metastatic breast cancer women and those whit operable breast cancer patients prior to before and 7 days after surgery.
  • PATIENTS AND METHODS: The study included 50 women with breast cancer, 22 of whom had metastatic disease.
  • HER 2 expression and serum levels of PRL were evaluated by fluorescence in situ hybridization (FISH) method and immunoradiometric assay (IRMA) method, respectively.
  • CONCLUSION: These preliminary results show that metastatic cancer-related hyperprolactinemia and lack of surgery-induced hyperprolactinemia are statistically more frequent in HER2-positive patients, thus suggesting a link between PRL endogenous secretion and HER2 expression in breast cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. Hyperprolactinemia / genetics. Mastectomy / psychology. Prolactin / blood. Receptor, ErbB-2 / genetics
  • [MeSH-minor] DNA, Neoplasm / analysis. Female. Humans. Immunoradiometric Assay. In Situ Hybridization, Fluorescence. Postoperative Complications / blood. Postoperative Period. Receptors, Estrogen


25. Friedrich I, Eizenbach M, Sajman J, Ben-Bassat H, Levitzki A: A cellular screening assay to test the ability of PKR to induce cell death in mammalian cells. Mol Ther; 2005 Nov;12(5):969-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PKR can be selectively activated in glioblastoma cells by in situ generation of dsRNA following introduction of antisense RNA complementary to an RNA expressed specifically in these cells.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Death / drug effects. Drug Screening Assays, Antitumor / methods. Glioblastoma / pathology. Ribonucleoproteins / therapeutic use. eIF-2 Kinase / pharmacology
  • [MeSH-minor] Animals. Breast Neoplasms / pathology. Cell Line, Tumor. Colonic Neoplasms / pathology. Hepatitis Delta Virus. Humans. Male. Mammals. Plasmids. Prostatic Neoplasms / pathology. RNA, Small Interfering

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16084774.001).
  • [ISSN] 1525-0016
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 0 / Ribonucleoproteins; EC 2.7.11.1 / eIF-2 Kinase
  •  go-up   go-down


26. Boissan M, De Wever O, Lizarraga F, Wendum D, Poincloux R, Chignard N, Desbois-Mouthon C, Dufour S, Nawrocki-Raby B, Birembaut P, Bracke M, Chavrier P, Gespach C, Lacombe ML: Implication of metastasis suppressor NM23-H1 in maintaining adherens junctions and limiting the invasive potential of human cancer cells. Cancer Res; 2010 Oct 1;70(19):7710-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our findings reveal that NM23-H1 is critical for control of cell-cell adhesion and cell migration at early stages of the invasive program in epithelial cancers, orchestrating a barrier against conversion of in situ carcinoma into invasive malignancy.
  • [MeSH-minor] Actins / metabolism. Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Cell Line, Tumor. Cell Movement / genetics. Colonic Neoplasms / genetics. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. Cytoskeleton / metabolism. Cytoskeleton / pathology. Gene Silencing. Humans. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. Liver Neoplasms / pathology. Matrix Metalloproteinase 14 / metabolism. Neoplasm Invasiveness. Wnt Proteins / metabolism


27. Aulmann S, Elsawaf Z, Penzel R, Schirmacher P, Sinn HP: Invasive tubular carcinoma of the breast frequently is clonally related to flat epithelial atypia and low-grade ductal carcinoma in situ. Am J Surg Pathol; 2009 Nov;33(11):1646-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive tubular carcinoma of the breast frequently is clonally related to flat epithelial atypia and low-grade ductal carcinoma in situ.
  • Low-grade precursor lesions, such flat epithelial atypia (FEA), low-grade ductal carcinoma in situ (lg-DCIS), and lobular neoplasia (LN) often coexist with invasive tubular carcinomas (TCs) of the breast.
  • Our data indicate, that in the majority of cases lg-DCIS and FEA are directly related to tubular breast cancer with a possible precursor role.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / pathology

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19675453.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Mitochondrial; 0 / DNA, Neoplasm
  •  go-up   go-down


28. Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J: Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol; 2005 Feb;16(2):273-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: HER-2/neu gene amplification has predictive value in breast cancer patients responding to trastuzumab.
  • PATIENTS AND METHODS: The frequency of HER-2/neu and Topoisomerase IIalpha gene amplification was studied in adenocarcinomas of the stomach (n=131) and the gastroesophageal junction (n=100) by chromogenic in situ hybridization (CISH).
  • Sensitivity of a gastric cancer cell line N87 with HER-2/neu amplification to trastuzumab was studied by a cell viability assay and compared with that of a HER-2 amplified breast cancer cell line SKBR-3.
  • HER-2/neu amplification was more common in the intestinal histologic type of gastric cancer (21.5%) than in the diffuse (2%) or the mixed/anaplastic type (5%, P=0.0051), but it was not associated with gender, age at diagnosis or clinical stage.
  • HER-2/neu targeting antibody trastuzumab inhibited the growth of a p185(HER-2/neu) overexpressing gastric and breast carcinoma cell lines (N87 and SKBR-3) with equal efficacy.


29. Graham AD, Faratian D, Rae F, Thomas JS: Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization. Histopathology; 2008 Jun;52(7):847-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization.
  • AIMS: To compare tissue microarray (TMA) and whole-section (WS) techniques in the routine assessment of HER-2 status in invasive breast cancer by immunohistochemistry and fluorescence in situ hybridization (FISH).
  • METHODS AND RESULTS: HER-2 status was assessed prospectively in 106 consecutive cases of excised high-grade and/or node-positive breast carcinoma using both WS- and TMA-based techniques.
  • CONCLUSIONS: TMA technology is a robust method of assessing HER-2 status in invasive breast cancer.
  • [MeSH-major] Breast Neoplasms / metabolism. Immunohistochemistry. In Situ Hybridization, Fluorescence. Receptor, ErbB-2 / metabolism. Tissue Array Analysis / methods
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Lobular / genetics. Carcinoma, Lobular / metabolism. DNA, Neoplasm / analysis. Female. Humans. Prospective Studies. Reproducibility of Results


30. Elloul S, Elstrand MB, Nesland JM, Tropé CG, Kvalheim G, Goldberg I, Reich R, Davidson B: Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer; 2005 Apr 15;103(8):1631-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.
  • For the current study, the authors analyzed the relation between the expression of Snail, Slug, and Sip1; the expression of MMP-2 and E-cadherin; and clinical parameters in patients with metastatic ovarian and breast carcinoma.
  • METHODS: One hundred one fresh-frozen, malignant effusions from patients who were diagnosed with gynecologic carcinomas (78 ovarian carcinomas and 23 breast carcinomas) were studied for mRNA expression of Snail, Slug, Sip1, MMP-2, and E-cadherin using reverse transcriptase-polymerase chain reaction analysis.
  • Snail mRNA and E-cadherin protein expression levels also were studied in ovarian carcinoma effusions using in situ hybridization and immunocytochemistry.
  • RESULTS: E-cadherin mRNA expression was lower in breast carcinoma (P = 0.001), whereas Snail expression was higher (P = 0.003).
  • The Snail/E-cadherin ratio (P < 0.001) and the Sip1/E-cadherin ratio (P = 0.002) were higher in breast carcinomas.
  • The Sip1/E-cadherin ratio was higher in primary ovarian carcinomas at the time of diagnosis compared with postchemotherapy ovarian carcinoma effusions (P = 0.003), higher in Stage IV tumors compared with Stage III tumors (P = 0.049), and higher in pleural effusions compared with peritoneal effusions (P = 0.044).
  • High Snail mRNA expression predicted shorter effusion-free survival (P = 0.008), disease-free survival (P = 0.03), and overall survival (P = 0.008) in patients with breast carcinoma.
  • CONCLUSIONS: Transcription factors that regulate E-cadherin were expressed differentially in metastatic ovarian and breast carcinoma.
  • Snail may predict a poor outcome in patients who have breast carcinoma metastatic to effusions.
  • This finding was in agreement with the stronger suppression of E-cadherin by Snail and Sip1 in breast carcinoma effusions, a clinical condition associated with extremely poor survival.
  • [MeSH-major] Breast Neoplasms / genetics. DNA-Binding Proteins / genetics. Drosophila Proteins / genetics. Gene Expression Regulation, Neoplastic. Homeodomain Proteins / genetics. Ovarian Neoplasms / genetics. Repressor Proteins / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / secondary. Adult. Aged. Cadherins / genetics. Cadherins / metabolism. Carcinoma, Ductal / genetics. Carcinoma, Ductal / metabolism. Carcinoma, Ductal / secondary. Carcinoma, Lobular / genetics. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / secondary. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / secondary. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Matrix Metalloproteinase 2 / genetics. Matrix Metalloproteinase 2 / metabolism. Middle Aged. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15742334.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / DNA-Binding Proteins; 0 / Drosophila Proteins; 0 / Homeodomain Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Repressor Proteins; 0 / Transcription Factors; 0 / ZEB2 protein, human; 0 / snail family transcription factors; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


31. Downs-Kelly E, Yoder BJ, Stoler M, Tubbs RR, Skacel M, Grogan T, Roche P, Hicks DG: The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol; 2005 Sep;29(9):1221-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study.
  • Breast carcinomas with amplification of HER2 on chromosome 17 are associated with HER2 protein overexpression, adversely affecting prognosis and predicting response to Herceptin therapy.
  • This impact was investigated in breast carcinomas identified by fluorescence in situ hybridization (FISH) to have a gain of chromosome 17 (CEP17+; n = 56), using a dual probe assay, which detects HER2 gene copy number and enumerates chromosome 17 (HER2/CEP17; Vysis).
  • A subgroup was evaluated by isotopic in situ hybridization for HER2 mRNA expression.
  • Isotopic in situ hybridization for HER2 mRNA performed on 26 CEP17+ cases (16 IHC 0-1+, 10 IHC 2+ or 3+) showed no increased HER2 mRNA expression (normalized to beta-actin mRNA).
  • These results suggest that chromosome 17 polysomy in the absence of HER2 amplification does not have a significant biologic influence on HER2 gene expression in breast carcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. Chromosomes, Human, Pair 17 / genetics. Genes, erbB-2 / physiology
  • [MeSH-minor] Female. Gene Dosage. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. RNA, Messenger / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16096413.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger
  •  go-up   go-down


32. Colleau M, Magalon G, Bonnier P: [Breast carcinoma diagnosed from surgical specimens. Retrospective study on three years]. Ann Chir Plast Esthet; 2005 Apr;50(2):127-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Breast carcinoma diagnosed from surgical specimens. Retrospective study on three years].
  • In the wake of three consecutive cases of microscopical examination of resection specimens following breast reduction revealing an adenocarcinoma, we wanted to point out the interest of a complete preoperative senological examination including mammography and postoperative anatomopathological examination.
  • We found seven patients (0.83%) with malignant breast cancer diagnosed on anatomopathological examination, which is comparable to the incidence found in literature.
  • Of these seven cases there were four ductal adenocarcinomas (0.47%), all of them in situ (DCIS), and three lobular adenocarcinomas (0.36%) of which one invasive (ILA), one in situ (LCIS) and one mixed.
  • In our opinion this shows that breast reduction can help in tracking down breast cancer and underlines the need for systematic and meticulous microscopic examination of resection specimens after breast reduction.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / surgery. Mastectomy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15820598.001).
  • [ISSN] 0294-1260
  • [Journal-full-title] Annales de chirurgie plastique et esthétique
  • [ISO-abbreviation] Ann Chir Plast Esthet
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


33. Oakley GJ 3rd, Tubbs RR, Crowe J, Sebek B, Budd GT, Patrick RJ, Procop GW: HER-2 amplification in tubular carcinoma of the breast. Am J Clin Pathol; 2006 Jul;126(1):55-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER-2 amplification in tubular carcinoma of the breast.
  • The prognostic and therapeutic implications of HER-2 gene amplification and estrogen and progesterone receptor status in breast cancer are well described.
  • To address the relative paucity of information concerning HER-2 amplification for tubular carcinomas, we assessed the frequency of gene amplification in 55 tubular carcinomas of the breast from 54 patients, 5 of which had axillary node metastases.
  • The HER-2 gene copy number was assessed by fluorescence in situ hybridization for the majority of tumors analyzed, whereas estrogen and progesterone receptor status was achieved by immunohistochemical analysis.
  • HER-2 gene amplification likely occurs infrequently, or not at all, in tubular carcinomas of the breast, whereas most express estrogen receptors.
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. Gene Amplification. Genes, erbB-2. Receptor, ErbB-2 / genetics
  • [MeSH-minor] Axilla. Biomarkers, Tumor / metabolism. Female. Gene Dosage. Humans. In Situ Hybridization, Fluorescence. Lymph Nodes / pathology. Lymphatic Metastasis. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16753605.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


34. Downs-Kelly E, Pettay J, Hicks D, Skacel M, Yoder B, Rybicki L, Myles J, Sreenan J, Roche P, Powell R, Hainfeld J, Grogan T, Tubbs R: Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast. Am J Surg Pathol; 2005 Nov;29(11):1505-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast.
  • Fluorescence in situ hybridization (FISH) has both excellent sensitivity and specificity in detecting HER2 gene amplification in invasive breast carcinoma.
  • The assay was performed on 94 invasive breast carcinomas, for which FISH (PathVysiontrade mark, Vysis, Downer's Grove, IL), conventional IHC (CB11), and enzyme metallography (EnzMettrade mark) results were known.
  • EnzMet is the first bright-field ISH assay in our experience that routinely and nonambiguously detects endogenous HER2 signals, essential for a reliable clinical HER2 assay, and in combination with HER2 protein enables improved diagnosis in borderline cases.
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. Genes, erbB-2 / immunology. Immunohistochemistry / methods. Receptor, ErbB-2 / immunology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16224218.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / 1R43 GM064257-01; United States / NCI NIH HHS / CA / 2R42CA83618-02; United States / NCI NIH HHS / CA / 5R42 CA083618-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


35. Yu J, Bhargava R, Dabbs DJ: Invasive lobular carcinoma with extracellular mucin production and HER-2 overexpression: a case report and further case studies. Diagn Pathol; 2010;5:36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Invasive lobular carcinomas (ILC) of breast typically demonstrate intracytoplasmic mucin.
  • We present a unique case of classical type ILC with abundant extracellular mucin and strong ERBB2 (HER2/neu) expression confirmed by immunohistochemistry and fluorescent in situ hybridization.
  • In addition, studies of tissue microarrays of 80 breast carcinomas with mucinous differentiation revealed 4 pure mucinous carcinomas showing significantly reduced E-cadherin staining without redistribution of p120 into cytoplasm.
  • The findings suggest that the presence of extracellular mucin does not exclude a diagnosis of lobular carcinoma, and the morphologic and molecular characteristics of lobular and ductal carcinomas are more complex than previously appreciated.
  • [MeSH-major] Adenocarcinoma, Mucinous / chemistry. Biomarkers, Tumor / analysis. Breast Neoplasms / chemistry. Carcinoma, Lobular / chemistry. Mucin-1 / analysis. Receptor, ErbB-2 / analysis
  • [MeSH-minor] Aged. Biopsy. Cadherins / analysis. Catenins / analysis. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Mastectomy, Segmental. Neoplasm Invasiveness. Tissue Array Analysis. Up-Regulation


36. Hong KM, Yang SH, Chowdhuri SR, Player A, Hames M, Fukuoka J, Meerzaman D, Dracheva T, Sun Z, Yang P, Jen J: Inactivation of LLC1 gene in nonsmall cell lung cancer. Int J Cancer; 2007 Jun 1;120(11):2353-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By in situ hybridization, we observed that LLC1 message is localized in normal lung bronchial epithelial cells but absent in 13 of 14 lung adenocarcinoma and 9 out of 10 lung squamous carcinoma samples.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2001 Nov 22;20(53):7699-709 [11753648.001]
  • [Cites] Nat Med. 2002 Aug;8(8):816-24 [12118244.001]
  • [Cites] Oncogene. 2003 Mar 13;22(10):1580-8 [12629521.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1596-601 [12670910.001]
  • [Cites] Breast Cancer Res Treat. 2003 Apr;78(3):337-45 [12755492.001]
  • [Cites] Int J Cancer. 2003 Nov 1;107(2):238-43 [12949800.001]
  • [Cites] Eur J Surg Oncol. 2003 Dec;29(10):900-3 [14624785.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):2042-54 [14627790.001]
  • [Cites] J Mol Diagn. 2004 May;6(2):90-5 [15096563.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4314-24 [15240517.001]
  • [Cites] Hum Pathol. 2004 Oct;35(10):1196-209 [15492986.001]
  • [Cites] Science. 1995 Oct 20;270(5235):484-7 [7570003.001]
  • [Cites] Nat Med. 1995 Jul;1(7):686-92 [7585152.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Science. 1997 May 23;276(5316):1268-72 [9157888.001]
  • [Cites] Cancer Res. 1998 Dec 15;58(24):5690-4 [9865724.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):711-5 [10487828.001]
  • [Cites] Histol Histopathol. 2005 Apr;20(2):645-63 [15736067.001]
  • [Cites] Biotechniques. 2005 Mar;38(3):354, 356, 358 [15786801.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2106-10 [15788655.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3063-71 [15833835.001]
  • [Cites] Lung Cancer. 2005 Jun;48(3):299-306 [15892997.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15203-8 [11752463.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3340-6 [12067970.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Jul;31(3):282-7 [11391799.001]
  • [Cites] Int J Cancer. 2001 Feb 15;91(4):433-7 [11251963.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1309-13 [11245426.001]
  • [Cites] Chest. 2005 Jul;128(1):452-62 [16002972.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7466-72 [16885343.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):249-55 [11196170.001]
  • (PMID = 17304513.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CP / Z01 CP010165-05; United States / PHS HHS / / R01 80127; United States / NCI NIH HHS / CP / Z01 CP010162-05; United States / PHS HHS / / R0184354; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CP / Z01 CP010164-05; United States / PHS HHS / / 0510370
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / C20orf85 protein, human; 0 / DNA Primers; 0 / Proteins
  • [Other-IDs] NLM/ NIHMS18699; NLM/ PMC1907378
  •  go-up   go-down


37. Broekhuizen LN, Wijsman JH, Peterse JL, Rutgers EJ: The incidence and significance of micrometastases in lymph nodes of patients with ductal carcinoma in situ and T1a carcinoma of the breast. Eur J Surg Oncol; 2006 Jun;32(5):502-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence and significance of micrometastases in lymph nodes of patients with ductal carcinoma in situ and T1a carcinoma of the breast.
  • AIM: To report the incidence and predictive value of positive axillary nodes in ductal carcinoma in situ (DCIS) and T1a carcinoma of the breast.
  • All consecutive patients with primary breast cancer that were treated between 1989 and 1998 and who had undergone axillary dissection were selected.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / secondary. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / secondary. Lymphatic Metastasis / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Axilla. Carcinoma, Lobular / pathology. Carcinoma, Lobular / secondary. Female. Follow-Up Studies. Humans. Immunohistochemistry. Lymph Node Excision. Lymph Nodes / pathology. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Neoplastic Cells, Circulating / pathology. Retrospective Studies. Sentinel Lymph Node Biopsy. Survival Rate

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16569492.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


38. Hemminki K, Granström C, Chen B: The Swedish family-cancer database: update, application to colorectal cancer and clinical relevance. Hered Cancer Clin Pract; 2005;3(1):7-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer cases were retrieved from the Swedish Cancer Registry from 1958-2002, including over 1.2 million first and multiple primary cancers and in situ tumours.
  • Compared to previous versions, only 6.0% of deceased offspring with a cancer diagnosis lack any parental information.
  • We show one application of the Database in the study of familial risks in colorectal adenocarcinoma, with defined age-group and anatomic site specific analyses.
  • Useful risk estimates have been developed for familial breast and prostate cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2004 Jan 20;108(3):433-42 [14648711.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):969-74 [11286479.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):109-14 [14618624.001]
  • [Cites] Fam Cancer. 2003;2(2):87-93 [14574157.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):827-32 [12937124.001]
  • [Cites] Lancet. 2003 Jul 5;362(9377):39-41 [12853198.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1769-71 [12702560.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):919-32 [12621137.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1638-44 [12496055.001]
  • [Cites] Cancer. 2003 Jan 1;97(1 Suppl):230-5 [12491486.001]
  • [Cites] Eur J Cancer. 2002 Dec;38(18):2428-34 [12460788.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):105-9 [12455061.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1332-52 [12433710.001]
  • [Cites] Science. 2002 Sep 20;297(5589):2013 [12242432.001]
  • [Cites] Int J Cancer. 2002 May 10;99(2):229-37 [11979438.001]
  • [Cites] Int J Cancer. 2002 May 10;99(2):218-28 [11979437.001]
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):8-22 [11814067.001]
  • [Cites] Nat Genet. 2002 Feb;30(2):227-32 [11818965.001]
  • [Cites] Int J Cancer. 2001 Dec 1;94(5):743-8 [11745471.001]
  • [Cites] Lancet. 2001 Oct 27;358(9291):1389-99 [11705483.001]
  • [Cites] Am J Gastroenterol. 2001 Oct;96(10):2992-3003 [11693338.001]
  • [Cites] Br J Cancer. 2001 Feb 2;84(3):388-91 [11161404.001]
  • [Cites] N Engl J Med. 2000 Jul 13;343(2):78-85 [10891514.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(11):2193-200 [10829038.001]
  • [Cites] Nat Genet. 2004 Dec;36(12):1312-8 [15543147.001]
  • [Cites] J Med Genet. 2004 Nov;41(11):801-7 [15520403.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 2;91(11):916-32 [10359544.001]
  • [Cites] Int J Oncol. 1998 Mar;12(3):701-10 [9472113.001]
  • [Cites] Nature. 1998 Jan 8;391(6663):184-7 [9428765.001]
  • [Cites] Int J Cancer. 1996 Nov 15;68(4):428-35 [8945611.001]
  • [Cites] Br Med Bull. 1994 Jul;50(3):527-35 [7987639.001]
  • [Cites] Cancer Detect Prev. 1995;19(3):219-33 [7750110.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 2;86(21):1600-8 [7932824.001]
  • [Cites] J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86 [2593165.001]
  • [Cites] Am J Epidemiol. 1990 Jun;131(6):961-72 [2188501.001]
  • [Cites] Int J Cancer. 2004 Jun 10;110(2):291-4 [15069696.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3375-6 [12947078.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):809-10 [15252856.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1253-6 [15247139.001]
  • [Cites] Stat Med. 2004 Apr 15;23(7):1111-30 [15057881.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):554-8 [14991577.001]
  • [Cites] J Med Genet. 2004 Feb;41(2):81-91 [14757853.001]
  • [Cites] Gastroenterology. 2001 Oct;121(4):830-8 [11606497.001]
  • [Cites] Gastroenterology. 2001 Aug;121(2):282-301 [11487538.001]
  • [Cites] J Med Genet. 2003 Nov;40(11):807-14 [14627668.001]
  • (PMID = 20223029.001).
  • [ISSN] 1897-4287
  • [Journal-full-title] Hereditary cancer in clinical practice
  • [ISO-abbreviation] Hered Cancer Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Other-IDs] NLM/ PMC2837068
  •  go-up   go-down


39. Wheeler DT, Kurman RJ: The relationship of glands to thick-wall blood vessels as a marker of invasion in endocervical adenocarcinoma. Int J Gynecol Pathol; 2005 Apr;24(2):125-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship of glands to thick-wall blood vessels as a marker of invasion in endocervical adenocarcinoma.
  • Routinely stained slides were examined from 50 invasive endocervical adenocarcinomas (37 of usual type and 13 of minimal deviation type), 26 noninvasive lesions (14 cases of adenocarcinoma in situ, 7 cases of hyperplasia, 4 cases of tunnel clusters, 1 adenomyoma), and 20 normal cervices, including 7 with deep nabothian cysts.
  • In conclusion, close proximity of glands to thick-wall blood vessels (distance from the closest gland to a thick-wall vessel less than or equal to the thickness of the vessel wall) seems to be a useful feature in the diagnosis of invasive endocervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor. Cervix Uteri / blood supply. Neoplasm Invasiveness / diagnosis. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Predictive Value of Tests. Sensitivity and Specificity


40. Sung JS, Park KH, Kim YH: Genomic alterations of chromosome region 11p as predictive marker by array comparative genomic hybridization in lung adenocarcinoma patients. Cancer Genet Cytogenet; 2010 Apr 1;198(1):27-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic alterations of chromosome region 11p as predictive marker by array comparative genomic hybridization in lung adenocarcinoma patients.
  • To further validate the gain of chromosome 11p region that was identified by array CGH, fluorescence in situ hybridization (FISH) was performed.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosomes, Human, Pair 11. Comparative Genomic Hybridization / methods. DNA Copy Number Variations. Lung Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosome Aberrations. Female. Genetic Markers. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Recurrence

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20303011.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


41. Barros-Silva JD, Leitão D, Afonso L, Vieira J, Dinis-Ribeiro M, Fragoso M, Bento MJ, Santos L, Ferreira P, Rêgo S, Brandão C, Carneiro F, Lopes C, Schmitt F, Teixeira MR: Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer; 2009 Feb 10;100(3):487-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we evaluated the ERBB2 status in 463 gastric carcinomas using immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH), and compared the findings with histopathological characteristics and with disease-specific survival.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, erbB-2. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cross-Sectional Studies. Gene Amplification. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genomics. 1989 Apr;4(3):362-6 [2565881.001]
  • [Cites] Oncogene. 1989 Jan;4(1):81-8 [2563577.001]
  • [Cites] Hum Pathol. 1990 Mar;21(3):325-32 [2312109.001]
  • [Cites] Mod Pathol. 1992 Jul;5(4):384-90 [1353880.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3942-6 [8099528.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1441-7 [8336183.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3845-52 [8033105.001]
  • [Cites] Int Surg. 1994 Jan-Mar;79(1):27-32 [8063551.001]
  • [Cites] Oncogene. 1997 Jul 31;15(5):537-47 [9247307.001]
  • [Cites] Lab Invest. 1998 Mar;78(3):345-51 [9520947.001]
  • [Cites] J Gastrointest Surg. 1998 Mar-Apr;2(2):126-31 [9834407.001]
  • [Cites] Cancer. 1999 May 1;85(9):1894-902 [10223227.001]
  • [Cites] Oncogene. 1999 Apr 1;18(13):2241-51 [10327070.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):255-62 [15517369.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):273-8 [15668283.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Clin Breast Cancer. 2005 Aug;6(3):240-6 [16137435.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1659-72 [16236737.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1673-84 [16236738.001]
  • [Cites] World J Surg. 2005 Nov;29(11):1422-7; discussion 1428 [16222448.001]
  • [Cites] Gastric Cancer. 2005;8(4):249-52 [16328600.001]
  • [Cites] Dig Dis Sci. 2006 Aug;51(8):1371-9 [16868827.001]
  • [Cites] Mol Syst Biol. 2006;2:54 [17016520.001]
  • [Cites] Cell Oncol. 2006;28(5-6):283-94 [17167181.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1386-93 [17555797.001]
  • [Cites] Eur J Cancer. 1999 Jul;35(7):1059-64 [10533448.001]
  • [Cites] Eur J Cancer. 2000 Feb;36(3):390-6 [10708942.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):16-7 [10973239.001]
  • [Cites] Ann Oncol. 2000 Jul;11(7):837-43 [10997811.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3651-64 [11054438.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):556-62 [11406656.001]
  • [Cites] Acta Oncol. 2001;40(2-3):309-26 [11441938.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1178-80 [11583204.001]
  • [Cites] Am J Clin Oncol. 2002 Feb;25(1):84-9 [11823704.001]
  • [Cites] Int J Cancer. 2002 Apr 20;98(6):833-7 [11948459.001]
  • [Cites] World J Gastroenterol. 2002 Dec;8(6):1023-8 [12439918.001]
  • [Cites] J Pathol. 2003 Apr;199(4):418-23 [12635131.001]
  • [Cites] Eur J Surg. 2002;168(11):597-608 [12699095.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):548-53 [14991576.001]
  • [Cites] Cancer. 1977 Jun;39(6):2475-85 [872047.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Dec;81(23):7308-12 [6095284.001]
  • [Cites] Science. 1986 Jun 27;232(4758):1644-6 [3012781.001]
  • [Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]
  • (PMID = 19156142.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2658544
  •  go-up   go-down


42. Kulka J, Tôkés AM, Kaposi-Novák P, Udvarhelyi N, Keller A, Schaff Z: Detection of HER-2/neu gene amplification in breast carcinomas using quantitative real-time PCR - a comparison with immunohistochemical and FISH results. Pathol Oncol Res; 2006;12(4):197-204
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of HER-2/neu gene amplification in breast carcinomas using quantitative real-time PCR - a comparison with immunohistochemical and FISH results.
  • The aim of our study was to evaluate the value of quantitative real-time-PCR (qPCR) in the determination of HER-2/neu amplification status of human breast carcinomas by comparing qPCR, FISH and immunohistochemistry results from the same samples.
  • A total of 210 breast carcinomas were examined.
  • In conclusion, a well calibrated HER-2/neu qPCR assay may serve as useful alternative to FISH in breast cancer patients.
  • [MeSH-major] Breast Neoplasms / genetics. Gene Amplification. Gene Expression Regulation, Neoplastic. Receptor, ErbB-2 / genetics. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Female. Humans. Image Processing, Computer-Assisted / methods. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence / methods. Paraffin Embedding. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1988 Nov 10;319(19):1239-45 [2903446.001]
  • [Cites] J Clin Oncol. 2002 Jul 15;20(14):3095-105 [12118023.001]
  • [Cites] Am J Clin Pathol. 1999 Jul;112(1 Suppl 1):S53-67 [10396301.001]
  • [Cites] Oncogene. 2004 Jan 29;23(4):1010-3 [14647448.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1936-42 [8105035.001]
  • [Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]
  • [Cites] Int J Surg Pathol. 2004 Oct;12(4):311-8 [15494857.001]
  • [Cites] Mod Pathol. 1997 Aug;10(8):823-31 [9267826.001]
  • [Cites] Science. 1987 Jan 9;235(4785):177-82 [3798106.001]
  • [Cites] Am J Clin Pathol. 2000 Feb;113(2):251-8 [10664627.001]
  • [Cites] J Clin Pathol. 1992 Jan;45(1):16-20 [1346789.001]
  • [Cites] Magy Onkol. 2002;46(1):11-5 [12050677.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2597-602 [1348967.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):354-63 [11208826.001]
  • [Cites] J Pathol. 2001 Nov;195(4):422-8 [11745673.001]
  • [Cites] Am J Clin Pathol. 2001 Apr;115(4):504-11 [11293897.001]
  • [Cites] Int J Cancer. 1988 Dec 15;42(6):842-5 [2903851.001]
  • [Cites] Int J Cancer. 1998 May 18;76(4):459-63 [9590117.001]
  • [Cites] Int J Oncol. 2004 Oct;25(4):929-35 [15375542.001]
  • [Cites] Mod Pathol. 2000 Jan;13(1):37-45 [10658908.001]
  • [Cites] Int J Biol Markers. 2004 Jan-Mar;19(1):1-13 [15077921.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4393-9 [15958623.001]
  • [Cites] Breast. 2003 Apr;12(2):92-8 [14659337.001]
  • [Cites] Neoplasia. 2003 Mar-Apr;5(2):128-34 [12659685.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):854-63 [14990641.001]
  • [Cites] BMC Clin Pathol. 2006 Jan 18;6:2 [16420697.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):499-506 [14745865.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):1043-7 [14608539.001]
  • [Cites] Nature. 1986 Jan 16-22;319(6050):226-30 [3945311.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):599-605 [1548522.001]
  • [Cites] Int J Oncol. 1999 Apr;14(4):663-71 [10087312.001]
  • [Cites] J Mol Diagn. 2004 Feb;6(1):42-51 [14736826.001]
  • [Cites] Mod Pathol. 2000 Aug;13(8):866-73 [10955453.001]
  • [Cites] Int J Oncol. 2003 Nov;23(5):1285-92 [14532967.001]
  • [Cites] Arkh Patol. 2003 Jan-Feb;65(1):50-5 [12669615.001]
  • [Cites] Mayo Clin Proc. 2002 Feb;77(2):148-54 [11838648.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 16;313(3):709-15 [14697248.001]
  • [Cites] Mol Diagn. 2000 Sep;5(3):199-207 [11070154.001]
  • (PMID = 17189981.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


43. Dziadziuszko R, Merrick DT, Witta SE, Mendoza AD, Szostakiewicz B, Szymanowska A, Rzyman W, Dziadziuszko K, Jassem J, Bunn PA Jr, Varella-Garcia M, Hirsch FR: Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol; 2010 May 1;28(13):2174-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression.
  • IGF1R gene copy number was assessed by fluorescent in situ hybridization using customized probes (n = 181).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Squamous Cell / genetics. Gene Dosage. Gene Expression Regulation, Neoplastic. In Situ Hybridization, Fluorescence. Lung Neoplasms / genetics. Pulmonary Surgical Procedures. RNA, Messenger / analysis. Receptor, IGF Type 1 / genetics
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / genetics. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Aneuploidy. Carcinoma, Large Cell / chemistry. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / surgery. Disease-Free Survival. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Receptor, Epidermal Growth Factor / genetics. Reverse Transcriptase Polymerase Chain Reaction. Risk Assessment. Risk Factors. Time Factors. Tissue Array Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 1989 Nov;109(5):2495-507 [2553748.001]
  • [Cites] Cancer Res. 1987 Nov 15;47(22):6126-33 [3664512.001]
  • [Cites] Endocr Relat Cancer. 2004 Dec;11(4):793-814 [15613453.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5900-9 [16043828.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):11118-28 [16322262.001]
  • [Cites] Thorax. 2006 Feb;61(2):140-5 [16284218.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3078-84 [16707605.001]
  • [Cites] Ann Oncol. 2006 Jul;17(7):1120-7 [16600976.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3798-807 [12953099.001]
  • [Cites] J Clin Oncol. 2009 May 20;27(15):2516-22 [19380445.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10100-11 [17047074.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5034-42 [17075123.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2795-803 [17473213.001]
  • [Cites] J Thorac Oncol. 2007 Aug;2(8):706-14 [17762336.001]
  • [Cites] Clin Cancer Res. 2007 Oct 1;13(19):5834-40 [17908976.001]
  • [Cites] Cancer. 2008 Mar 1;112(5):1114-21 [18219661.001]
  • [Cites] J Clin Oncol. 2008 Jul 10;26(20):3351-7 [18612151.001]
  • [Cites] Breast Cancer Res Treat. 2008 Sep;111(1):79-91 [17902048.001]
  • [Cites] J Thorac Oncol. 2008 Aug;3(8):815-8 [18670298.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6364-70 [18927274.001]
  • [Cites] J Natl Cancer Inst. 2008 Dec 3;100(23):1672-94 [19033571.001]
  • [Cites] Cancer Res. 2009 Jan 1;69(1):161-70 [19117999.001]
  • [Cites] Ann Oncol. 2009 May;20(5):842-9 [19153117.001]
  • [Cites] Control Clin Trials. 1996 Aug;17(4):343-6 [8889347.001]
  • (PMID = 20351332.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA058187; United States / NCI NIH HHS / CA / P50 CA058187
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, IGF Type 1
  • [Other-IDs] NLM/ PMC2860435
  •  go-up   go-down


44. Godoy A, Ulloa V, Rodríguez F, Reinicke K, Yañez AJ, García Mde L, Medina RA, Carrasco M, Barberis S, Castro T, Martínez F, Koch X, Vera JC, Poblete MT, Figueroa CD, Peruzzo B, Pérez F, Nualart F: Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol; 2006 Jun;207(3):614-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues.
  • GLUT2 was detected in 31% of the samples, being mainly expressed in breast, colon, and liver carcinoma.
  • GLUT5 was detected in 27% of breast and colon adenocarcinoma, liver carcinoma, lymphomas, and testis seminoma samples.
  • In situ RT-PCR and ultrastructural immunohistochemistry confirmed GLUT5 expression in breast cancer.
  • [MeSH-major] Breast / metabolism. Breast / pathology. Glucose Transport Proteins, Facilitative / metabolism. Neoplasms / metabolism. Neoplasms / pathology
  • [MeSH-minor] Animals. Biopsy. Gene Expression Regulation, Neoplastic. Health. Humans. Immunohistochemistry. In Situ Hybridization. Mice. Microscopy, Immunoelectron. Organ Specificity. Rats. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16523487.001).
  • [ISSN] 0021-9541
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transport Proteins, Facilitative
  •  go-up   go-down


45. Strumylaite L, Bogusevicius A, Ryselis S, Pranys D, Poskiene L, Kregzdyte R, Abdrachmanovas O, Asadauskaite R: [Association between cadmium and breast cancer]. Medicina (Kaunas); 2008;44(6):415-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Association between cadmium and breast cancer].
  • Cadmium is a known human lung carcinogen, although some studies indicate a link between cadmium exposure and human breast cancer.
  • The objective of this study was to assess cadmium concentration in breast tissue samples of patients with breast cancer and benign breast tumor.
  • The concentration of cadmium was determined in breast tissue samples of 21 breast cancer and 19 benign tumor patients.
  • Two samples of breast tissue from each patient, i.e. tumor and normal tissue close to tumor, were taken for the analysis.
  • RESULTS. In patients with breast cancer, the mean cadmium concentration was 33.1 ng/g (95% CI, 21.9-44.4) in malignant breast tissue and 10.4 ng/g (95% CI, 5.6-15.2) in normal breast tissue (P=0.002).
  • There was a statistically significant difference in cadmium concentration between malignant and benign breast tissues (P=0.009).
  • CONCLUSION. The data obtained show that cadmium concentration is significantly higher in malignant breast tissue as compared with normal breast tissue of the same women or benign breast tissue.
  • Further studies are necessary to determine the association between cadmium concentration in malignant breast tissue and estrogen receptor level, and smoking.
  • [MeSH-major] Adenocarcinoma, Mucinous / chemistry. Breast / chemistry. Breast Neoplasms / chemistry. Cadmium / analysis. Carcinoma in Situ / chemistry. Carcinoma, Ductal, Breast / chemistry

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CADMIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18660635.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] lit
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Lithuania
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 00BH33GNGH / Cadmium
  •  go-up   go-down


46. Anagnostou VK, Lowery FJ, Zolota V, Tzelepi V, Gopinath A, Liceaga C, Panagopoulos N, Frangia K, Tanoue L, Boffa D, Gettinger S, Detterbeck F, Homer RJ, Dougenis D, Rimm DL, Syrigos KN: High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology. BMC Cancer; 2010;10:186
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AQUA(R), a fluorescent-based method for analysis of in situ protein expression, was used to measure Bcl-2 protein levels and classify tumors by Bcl-2 expression in a cohort of 180 NSCLC patients.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Carcinoma, Large Cell / chemistry. Carcinoma, Non-Small-Cell Lung / chemistry. Carcinoma, Squamous Cell / chemistry. Lung Neoplasms / chemistry. Proto-Oncogene Proteins c-bcl-2 / analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 2006 May;52(2):241-7 [16529843.001]
  • [Cites] Leuk Res. 2006 Mar;30(3):322-31 [16213584.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4697-705 [16892083.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):13-8 [11316541.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):105-10 [11823980.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4285-91 [12409326.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1323-7 [12389040.001]
  • [Cites] Chest. 2003 Jun;123(6):1858-67 [12796161.001]
  • [Cites] Cancer. 2003 Jul 1;98(1):135-43 [12833466.001]
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):55-64 [12838300.001]
  • [Cites] Lancet. 2003 Aug 9;362(9382):433-9 [12927430.001]
  • [Cites] Eur J Surg Oncol. 2003 Oct;29(8):654-7 [14511612.001]
  • [Cites] Lung Cancer. 2003 Dec;42(3):275-81 [14644514.001]
  • [Cites] Histopathology. 2004 Jan;44(1):54-63 [14717670.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3b):1925-8 [15274378.001]
  • [Cites] Nature. 1990 Nov 22;348(6299):334-6 [2250705.001]
  • [Cites] Cell. 1993 Aug 27;74(4):609-19 [8358790.001]
  • [Cites] Cancer Res. 1994 Jan 1;54(1):256-60 [8261449.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1994 Aug 30;345(1313):289-95 [7846127.001]
  • [Cites] Annu Rev Immunol. 1995;13:513-43 [7612233.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1227-32 [7590697.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9545-52 [8790367.001]
  • [Cites] Science. 1997 Dec 12;278(5345):1966-8 [9395403.001]
  • [Cites] Virchows Arch. 1998 May;432(5):441-4 [9645443.001]
  • [Cites] Trends Cell Biol. 1998 Aug;8(8):324-30 [9704409.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1305-8 [9721089.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1322-6 [9735050.001]
  • [Cites] Lung Cancer. 1998 Dec;22(3):181-90 [10048471.001]
  • [Cites] Br J Cancer. 1999 Feb;79(5-6):952-8 [10070896.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7252-9 [15534099.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7662-70 [15569999.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):677-81 [15902208.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5554-60 [15994927.001]
  • [Cites] J Natl Cancer Inst. 2005 Dec 21;97(24):1808-15 [16368942.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):389-99 [17097561.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] Oncogene. 2007 Feb 1;26(5):652-61 [16909121.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1176-83 [17283153.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Mar;15(1):31-7 [17536304.001]
  • [Cites] Chest. 2007 Sep;132(3 Suppl):277S-289S [17873174.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):870-6 [18281659.001]
  • [Cites] IUBMB Life. 2008 Jun;60(6):390-7 [18425793.001]
  • [Cites] Breast Cancer Res. 2008;10(2):R35 [18430249.001]
  • [Cites] Tumori. 2008 May-Jun;94(3):398-405 [18705409.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4180-8 [18757333.001]
  • [Cites] Am J Respir Cell Mol Biol. 2009 Feb;40(2):135-46 [18676776.001]
  • [Cites] J Thorac Oncol. 2009 Apr;4(4):486-91 [19240654.001]
  • [Cites] Lung Cancer. 2009 Sep;65(3):377-82 [19150580.001]
  • [Cites] Int J Clin Pract. 2006 Jun;60(6):675-82 [16805752.001]
  • (PMID = 20459695.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2
  • [Other-IDs] NLM/ PMC2875218
  •  go-up   go-down


47. Souazé F, Dupouy S, Viardot-Foucault V, Bruyneel E, Attoub S, Gespach C, Gompel A, Forgez P: Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression. Cancer Res; 2006 Jun 15;66(12):6243-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression.
  • In a series of 51 patients with invasive ductal breast cancers, 34% of all tumors were positive for neurotensin and 91% positive for NT1 receptor.
  • We found a coexpression of neurotensin and NT1 receptor in a large proportion (30%) of ductal breast tumors, suggesting a contribution of the neurotensinergic signaling cascade within breast cancer progression.
  • Functionally expressed NT1 receptor, in the highly malignant MDA-MB-231 human breast cancer cell line, coordinated a series of transforming functions, including cellular migration, invasion, induction of the matrix metalloproteinase (MMP)-9 transcripts, and MMP-9 gelatinase activity.
  • Our findings support the contribution of neurotensin in human breast cancer progression and point out the utility to develop therapeutic molecules targeting neurotensin or NT1 receptor signaling cascade.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Neurotensin / biosynthesis. Receptors, Neurotensin / biosynthesis
  • [MeSH-minor] Animals. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Cell Growth Processes / physiology. Cell Line, Tumor. Cell Movement / physiology. Disease Progression. Enzyme Activation. Female. Humans. Immunohistochemistry. Matrix Metalloproteinase 9 / metabolism. Mice. Middle Aged. Neoplasm Invasiveness. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16778199.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Neurotensin; 0 / neurotensin type 1 receptor; 39379-15-2 / Neurotensin; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


48. Bransfield KL, Askham JM, Leek JP, Robinson PA, Mighell AJ: Phenotypic changes associated with DYNACTIN-2 (DCTN2) over expression characterise SJSA-1 osteosarcoma cells. Mol Carcinog; 2006 Mar;45(3):157-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma. Bone Neoplasms / genetics. Breast Neoplasms. Cell Line, Tumor. Colonic Neoplasms. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Osteosarcoma / genetics. Phenotype. Rectal Neoplasms

  • Genetic Alliance. consumer health - Osteosarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16369996.001).
  • [ISSN] 0899-1987
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Microtubule-Associated Proteins; 144198-36-7 / dynactin
  •  go-up   go-down


49. Rüschoff J, Nagelmeier I, Baretton G, Dietel M, Höfler H, Schildhaus HU, Büttner R, Schlake W, Stoss O, Kreipe HH: [Her2 testing in gastric cancer. What is different in comparison to breast cancer?]. Pathologe; 2010 May;31(3):208-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Her2 testing in gastric cancer. What is different in comparison to breast cancer?].
  • Based on data from a large multicenter phase III trial (ToGA study) trastuzumab has very recently been approved by the EMEA for metastatic gastric cancer and adenocarcinoma of the gastro-esophageal junction.
  • However, testing of Her2 status by immunohistochemistry (IHC) differs from breast cancer in core aspects: 1.
  • Evaluation of Her2 in situ hybridization (ISH) is similar to breast cancer with ratio values of > or =2.0 indicating Her2 gene amplification.
  • In contrast to breast cancer, up to one-third of gastric cancers show a heterogeneous Her2 status both at IHC and ISH levels which favors bright field ISH over FISH.
  • [MeSH-major] Breast Neoplasms / genetics. Receptor, ErbB-2 / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Algorithms. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Gene Amplification. Humans. In Situ Hybridization. In Situ Hybridization, Fluorescence. Neoplasm Metastasis


50. Nicolas MM, Nayar R, Yeldandi A, De Frias DV: Pulmonary metastasis of a postradiation breast epithelioid angiosarcoma mimicking adenocarcinoma. A case report. Acta Cytol; 2006 Nov-Dec;50(6):672-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary metastasis of a postradiation breast epithelioid angiosarcoma mimicking adenocarcinoma. A case report.
  • We report a case of metastatic postradiation EAS to the lungs that was mistaken for adenocarcinoma.
  • CASE: A 45-year-old woman who received radiotherapy for ductal carcinoma in situ (DCIS) 5 years previously had a local recurrence a year earlier and recent development of bilateral small pulmonary nodules.
  • An interpretation of adenocarcinoma was rendered during assessment for specimen adequacy.
  • The original breast tumor was typical of cribriform DCIS.
  • Review of the recurrent breast tumor (initially reported as DCIS) and a prior wedge resection of the lung nodules (reported as EAS) showed an epithelial-appearing tumor exhibiting an endothelial immunophenotype CONCLUSION: The cytologic features of EAS may resemble those of other neoplasms.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / radiotherapy. Hemangiosarcoma / secondary. Lung Neoplasms / secondary. Neoplasms, Radiation-Induced / pathology. Radiotherapy / adverse effects
  • [MeSH-minor] Biopsy, Fine-Needle / methods. Diagnosis, Differential. Epithelioid Cells / pathology. Female. Humans. Middle Aged


51. de Candia P, Akram M, Benezra R, Brogi E: Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma. Hum Pathol; 2006 Aug;37(8):1032-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma.
  • We assessed the expression of Id4 messenger RNA (mRNA) in invasive mammary carcinoma from 31 patients, as well as in 21 cases of ductal carcinoma in situ, in 9 lymph node metastases, and in the morphologically normal epithelium adjacent to the carcinoma from the same subjects.
  • In addition, we evaluated Id4 mRNA in atypical ductal hyperplasia from 5 other women and in normal breast tissue from yet another 5 women with no history of breast malignancy or atypia.
  • Id4 mRNA was present in the normal ER-negative mammary epithelium in all cases; in contrast, the ER-positive cells present in the normal breast were Id4 negative.
  • Id4 mRNA was not detected in atypical ductal hyperplasia, in 22 of the 23 cases of ductal carcinoma in situ, and in 27 of the 31 invasive carcinomas (P = .0008), all of which were ER positive.
  • Our data show that Id4 is constitutively expressed in the normal human mammary epithelium but is suppressed in ER-positive breast carcinomas and preneoplastic lesions.
  • These results support a possible role of Id4 as a tumor suppressor factor in the human breast and suggest that the expression of Id4 in the mammary ductal epithelium may be regulated by estrogen.
  • Further investigations are required to define the functions of Id4 in the human normal breast and in mammary neoplasia.
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. Helix-Loop-Helix Motifs. Inhibitor of Differentiation Proteins / genetics. RNA, Messenger / metabolism. Receptors, Estrogen / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast / cytology. Breast / metabolism. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / secondary. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / genetics. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / secondary. Epithelial Cells / cytology. Epithelial Cells / metabolism. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Middle Aged. Neoplasm Staging. RNA, Neoplasm / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16867866.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ID4 protein, human; 0 / Inhibitor of Differentiation Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, Estrogen
  •  go-up   go-down


52. Xie D, Sham JS, Zeng WF, Lin HL, Bi J, Che LH, Hu L, Zeng YX, Guan XY: Correlation of AIB1 overexpression with advanced clinical stage of human colorectal carcinoma. Hum Pathol; 2005 Jul;36(7):777-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIB1, a member of the steroid receptor coactivator 1 family, has been cloned on 20q12 and is a candidate oncogene in human breast cancer.
  • [MeSH-major] Acetyltransferases / metabolism. Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Oncogene Proteins / metabolism. Trans-Activators / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aneuploidy. Cell Nucleus / metabolism. Cell Nucleus / pathology. DNA, Neoplasm / analysis. Female. Flow Cytometry. Gene Amplification. Histone Acetyltransferases. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Male. Middle Aged. Nuclear Receptor Coactivator 3. Protein Array Analysis. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16084947.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Oncogene Proteins; 0 / Trans-Activators; 0 / Tumor Suppressor Protein p53; EC 2.3.1.- / Acetyltransferases; EC 2.3.1.48 / Histone Acetyltransferases; EC 2.3.1.48 / NCOA3 protein, human; EC 2.3.1.48 / Nuclear Receptor Coactivator 3
  •  go-up   go-down


53. Chu QD, Sun L, Li J, Byrnes K, Chervenak D, DeBenedetti A, Mathis JM, Li BD: Rat adenocarcinoma cell line infected with an adenovirus carrying a novel herpes-simplex virus-thymidine kinase suicide gene construct dies by apoptosis upon treatment with ganciclovir. J Surg Res; 2007 Nov;143(1):189-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rat adenocarcinoma cell line infected with an adenovirus carrying a novel herpes-simplex virus-thymidine kinase suicide gene construct dies by apoptosis upon treatment with ganciclovir.
  • This protein has been found in elevated quantities in breast, colon, and head and neck cancers.
  • In this study, we investigated the in vitro activity of this suicide gene therapy against the rat Mat BIII breast adenocarcinoma cell line, and assessed whether apoptosis was the responsible mechanism of cell killing.
  • Induction of apoptosis was determined using annexin V-FITC and propidium iodine detection kit and a terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling in situ cell death detection kit.
  • CONCLUSION: Suicide gene therapy targeting the overexpression of eIF4E induces apoptosis and cell death in rat Mat BIII mammary adenocarcinoma cells.
  • [MeSH-major] Adenocarcinoma / therapy. Apoptosis / drug effects. Eukaryotic Initiation Factor-4E / metabolism. Ganciclovir / pharmacology. Genes, Transgenic, Suicide. Mammary Neoplasms, Animal / therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17950092.001).
  • [ISSN] 0022-4804
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Eukaryotic Initiation Factor-4E; 0 / Fluorescent Dyes; EC 2.7.1.21 / Thymidine Kinase; I223NX31W9 / Fluorescein-5-isothiocyanate; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


54. Marx AH, Tharun L, Muth J, Dancau AM, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Brümmendorf TH, Bokemeyer C, Izbicki JR, Sauter G: HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol; 2009 Jun;40(6):769-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Her-2 is the molecular target for antibody-based treatment of breast cancer (trastuzumab).
  • To address the potential applicability of trastuzumab in gastric cancer, tissue microarray sections of 166 gastric adenocarcinomas and 69 lymph node metastases were analyzed for Her-2 overexpression and amplification using Food and Drug Administration-approved reagents for immunohistochemistry and fluorescence in situ hybridization.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, erbB-2 / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antigens, Neoplasm / genetics. DNA Topoisomerases, Type II / genetics. DNA-Binding Proteins / genetics. Female. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Lymphatic Metastasis. Male. Middle Aged. Receptor, ErbB-2 / immunology. Tissue Array Analysis. Trastuzumab

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2011 Jun;42(6):909-10; author reply 910-1 [21571126.001]
  • [CommentIn] Hum Pathol. 2010 Feb;41(2):304-5; author reply 305-6 [19914678.001]
  • (PMID = 19269014.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha; P188ANX8CK / Trastuzumab
  •  go-up   go-down


55. Marx AH, Burandt EC, Choschzick M, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Atanackovic D, Bokemeyer C, Fiedler W, Terracciano L, Sauter G, Izbicki JR: Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Hum Pathol; 2010 Nov;41(11):1577-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HER-2 is the molecular target for antibody-based treatment of breast cancer (trastuzumab).
  • To address the potential applicability of anti-HER-2 therapy in colorectal cancer, tissue microarray sections and colorectal resection specimens of 1851 colorectal cancers were analyzed for HER-2 overexpression and amplification using FDA approved reagents for immunohistochemistry and fluorescence in situ hybridization.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. Gene Amplification / genetics. Genes, erbB-2 / genetics. Receptor, ErbB-2 / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA, Neoplasm / analysis. Female. Germany / epidemiology. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Male. Middle Aged. Survival Rate. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20656317.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


56. Abdel-Fatah TM, Powe DG, Hodi Z, Lee AH, Reis-Filho JS, Ellis IO: High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol; 2007 Mar;31(3):417-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma.
  • This study was undertaken to determine the morphologic features and frequency of putative precursor lesions involved in the development of some pure forms of special types and low grade breast carcinoma.
  • The presence of preinvasive lesions including columnar cell lesions (CCLs), usual epithelial hyperplasia, ductal carcinoma in situ (DCIS), and lobular neoplasia (LN) was determined.
  • Our observations suggest that these lesions represent family members of low grade precursor, in situ and invasive neoplastic lesions of the breast.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / pathology. Epithelial Cells / pathology. Precancerous Conditions / pathology


57. Gallego R, Pintos E, García-Caballero T, Raghay K, Boulanger L, Beiras A, Gaudreau P, Morel G: Cellular distribution of growth hormone-releasing hormone receptor in human reproductive system and breast and prostate cancers. Histol Histopathol; 2005 07;20(3):697-706
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular distribution of growth hormone-releasing hormone receptor in human reproductive system and breast and prostate cancers.
  • Moreover, GHRH-R was demonstrated in prostate and breast carcinomas, opening a variety of possibilities for the use of GHRH antagonists in the treatment of prostatic and mammary tumors.
  • [MeSH-major] Breast Neoplasms / metabolism. Ovary / metabolism. Prostatic Neoplasms / metabolism. Receptors, Neuropeptide / metabolism. Receptors, Pituitary Hormone-Regulating Hormone / metabolism. Testis / metabolism
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Female. Humans. Immunohistochemistry. In Situ Hybridization. Male. Mammary Glands, Human / metabolism. Placenta / metabolism. Pregnancy. RNA, Messenger / genetics. RNA, Messenger / metabolism. Uterus / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15944917.001).
  • [ISSN] 0213-3911
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Neuropeptide; 0 / Receptors, Pituitary Hormone-Regulating Hormone; 0 / somatotropin releasing hormone receptor
  •  go-up   go-down


58. Kikuchi Y, Kashima TG, Nishiyama T, Shimazu K, Morishita Y, Shimazaki M, Kii I, Horie H, Nagai H, Kudo A, Fukayama M: Periostin is expressed in pericryptal fibroblasts and cancer-associated fibroblasts in the colon. J Histochem Cytochem; 2008 Aug;56(8):753-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pericryptal pattern of periostin deposition was decreased in adenoma and adenocarcinoma, preceding the decrease of the number of pericryptal fibroblasts.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Cell Adhesion Molecules / biosynthesis. Colon / metabolism. Colonic Neoplasms / metabolism. Fibroblasts / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation. Cells, Cultured. Coculture Techniques. Collagen Type I. Gels. Humans. Immunohistochemistry. In Situ Hybridization. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Lung / cytology. Mice. Mice, Inbred ICR. Microscopy, Immunoelectron. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2001 Aug 15;92(4):843-8 [11550156.001]
  • [Cites] Mech Dev. 2001 May;103(1-2):183-8 [11335131.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):98-104 [11689954.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5358-64 [12235007.001]
  • [Cites] Breast Cancer Res Treat. 2003 Feb;77(3):245-52 [12602924.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):111-21 [14699493.001]
  • [Cites] Dev Dyn. 2004 Apr;229(4):857-68 [15042709.001]
  • [Cites] Mol Cell Biol. 2004 May;24(9):3992-4003 [15082792.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):329-39 [15093540.001]
  • [Cites] Hum Pathol. 1993 May;24(5):525-33 [8491492.001]
  • [Cites] Biochem J. 1993 Aug 15;294 ( Pt 1):271-8 [8363580.001]
  • [Cites] Annu Rev Cell Biol. 1993;9:511-40 [8280470.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1644-9 [9135000.001]
  • [Cites] J Physiol. 1999 Jan 1;514 ( Pt 1):211-27 [9831728.001]
  • [Cites] J Gastroenterol. 1999 Apr;34(2):215-20 [10213121.001]
  • [Cites] J Bone Miner Res. 1999 Jul;14(7):1239-49 [10404027.001]
  • [Cites] Pathol Int. 1999 May;49(5):426-34 [10417686.001]
  • [Cites] Am J Physiol. 1999 Aug;277(2 Pt 1):C183-201 [10444394.001]
  • [Cites] Anat Rec A Discov Mol Cell Evol Biol. 2004 Dec;281(2):1264-75 [15386274.001]
  • [Cites] Carcinogenesis. 2005 May;26(5):908-15 [15731169.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Apr 14;342(3):766-72 [16497272.001]
  • [Cites] J Allergy Clin Immunol. 2006 Jul;118(1):98-104 [16815144.001]
  • [Cites] J Biol Chem. 2006 Jul 14;281(28):19700-8 [16702213.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6928-35 [16849536.001]
  • [Cites] Breast Cancer Res. 2006;8(5):R56 [17014703.001]
  • [Cites] Oncogene. 2007 Mar 29;26(14):2082-94 [17043657.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1447-64 [17408641.001]
  • [Cites] J Cell Biochem. 2007 Jun 1;101(3):695-711 [17226767.001]
  • [Cites] J Exp Med. 2008 Feb 18;205(2):295-303 [18208976.001]
  • [Cites] Mod Pathol. 2008 Aug;21(8):1044-53 [18487994.001]
  • [Cites] J Bone Miner Metab. 2000;18(3):132-9 [10783846.001]
  • [Cites] J Lab Clin Med. 2000 Sep;136(3):201-8 [10985498.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Sep;16(9):991-1000 [11595063.001]
  • (PMID = 18443362.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / Collagen Type I; 0 / Gels; 0 / POSTN protein, human; 0 / Postn protein, mouse
  • [Other-IDs] NLM/ PMC2443605
  •  go-up   go-down


59. Anderson WF, Devesa SS: In situ male breast carcinoma in the Surveillance, Epidemiology, and End Results database of the National Cancer Institute. Cancer; 2005 Oct 15;104(8):1733-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In situ male breast carcinoma in the Surveillance, Epidemiology, and End Results database of the National Cancer Institute.
  • BACKGROUND: In situ breast carcinoma is not so well characterized for men as for women.
  • METHODS: Therefore, the authors of the current study compared male and female in situ and invasive breast carcinomas in the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute to document these patterns.
  • RESULTS: In situ breast carcinomas composed 9.4% of all male (n = 280 of 2984) and 11.9% of all female breast carcinomas (n = 53,928 of 454,405) during the years 1973-2001.
  • In situ rates rose 123% for men and 555% for women over this time period; whereas distant disease rates fell for both genders.
  • Median ages at diagnosis were 62 years for in situ and 68 years for invasive breast carcinoma among men, compared with 58 years for in situ and 62 years for invasive breast carcinoma among women.
  • Papillary in situ and invasive architectural types were more common among men than women.
  • Breast cancer-specific survival was similar among men and women, whereas overall survival was worse for men than women.
  • CONCLUSION: In situ male breast carcinoma is a rare disease, occurring at older ages and with different architectural types than its more common female counterpart.
  • Gender-specific histopathologic differences probably reflect anatomic differences among the normal female and vestigial male breast.
  • Rising in situ male breast carcinoma incidence rates over the past three decades suggest earlier detection over time, irrespective of mammography, because men do not participate in routine screening mammography.
  • [MeSH-major] Breast Neoplasms, Male / epidemiology. SEER Program / statistics & numerical data
  • [MeSH-minor] Adenocarcinoma, Mucinous / epidemiology. Aged. Aged, 80 and over. Breast Neoplasms / epidemiology. Carcinoma in Situ / epidemiology. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Invasiveness. Neoplasms, Ductal, Lobular, and Medullary / epidemiology. Risk Factors. Survival Rate. United States / epidemiology


60. Uzan C, Andre F, Scott V, Laurent I, Azria E, Suciu V, Balleyguier C, Lacroix L, Delaloge S, Vielh P: Fine-needle aspiration for nucleic acid-ased molecular analyses in breast cancer. Cancer; 2009 Feb 25;117(1):32-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration for nucleic acid-ased molecular analyses in breast cancer.
  • METHODS: Ultrasound- or palpation-guided FNAC was performed in 124 consecutive patients who had nodular breast lesions.
  • For malignant lesions, the authors attempted to correlate estrogen receptor 1 (ESR1) and HER-2 (c-erb-B2) mRNA expression measured by real-time quantitative polymerase chain reaction with estrogen receptor and HER-2 detection obtained by immunohistochemistry (IHC) and/or fluorescent in situ hybridization (FISH) on the surgical specimen.
  • The most significant predictors of quality and quantity of mRNA were the cytopathologist who sampled the tumors and a diagnosis of cancer versus benign lesion.
  • CONCLUSIONS: In 70% of cases, FNAC of breast lesions in well trained hands allowed the extraction of mRNA suitable for gene expression analysis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biopsy, Fine-Needle. Breast Neoplasms / diagnosis. RNA, Messenger / isolation & purification
  • [MeSH-minor] Estrogen Receptor alpha / biosynthesis. Estrogen Receptor alpha / genetics. Female. Gene Expression Profiling. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Middle Aged. Receptor, ErbB-2 / biosynthesis. Receptor, ErbB-2 / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 American Cancer Society.
  • (PMID = 19347827.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


61. Jensen KC, Nielsen TO, Gilks CB, West RB: HER2 Intermediate Breast Cancers. Am J Surg Pathol; 2009 Nov;33(11):1739; author reply 1739-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER2 Intermediate Breast Cancers.
  • [MeSH-major] Adenocarcinoma / chemistry. Breast Neoplasms / chemistry. Receptor, ErbB-2 / analysis
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Combined Modality Therapy. Female. Gene Dosage. Guidelines as Topic. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Prognosis. Trastuzumab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Am J Surg Pathol. 2009 May;33(5):759-67 [19252432.001]
  • (PMID = 19745698.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


62. Guest I, Ilic Z, Ma J, Grant D, Glinsky G, Sell S: Direct and indirect contribution of bone marrow-derived cells to cancer. Int J Cancer; 2010 May 15;126(10):2308-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One of the female FVB/N recipient mice also developed fibrosarcoma and 1, a diploid breast adenocarcinoma containing Y chromosomes.
  • These results indicate not only that the transgenic BM-derived stromal cells may indirectly contribute to development of tumors in recipient mice but also that sarcomas may arise by transformation of BM stem cells and that breast cancers arise by transdifferentiation of BM stem cells, presumably by mesenchymal-epithelial transition.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):183-93 [15300012.001]
  • [Cites] Mol Cancer Ther. 2004 Aug;3(8):941-53 [15299077.001]
  • [Cites] J Cell Biol. 2006 Mar 27;172(7):973-81 [16567498.001]
  • [Cites] Science. 2006 Mar 31;311(5769):1880-5 [16574858.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):392-401 [16572188.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4553-7 [16651403.001]
  • [Cites] Science. 2004 Nov 26;306(5701):1568-71 [15567866.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1755-60 [15753371.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):5991-5; discussion 5995 [16024595.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):5996-6000; discussion 6000-1 [16024596.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12):988-93 [16321767.001]
  • [Cites] Nature. 2006 Feb 23;439(7079):993-7 [16395311.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):8274-9 [16912208.001]
  • [Cites] Neoplasia. 2006 Sep;8(9):716-24 [16984729.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5615-21 [17020963.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:287-309 [16824016.001]
  • [Cites] Stem Cell Rev. 2005;1(1):1-7 [17132868.001]
  • [Cites] Dev Biol. 2007 Mar 1;303(1):29-44 [17222404.001]
  • [Cites] Stem Cells. 2007 Aug;25(8):1881-7 [17478582.001]
  • [Cites] Cancer Cell. 2008 Jan;13(1):58-68 [18167340.001]
  • [Cites] Cancer Res. 2008 Feb 15;68(4):989-97 [18281472.001]
  • [Cites] Stem Cells. 2008 Jul;26(7):1768-77 [18467658.001]
  • [Cites] Semin Cancer Biol. 2008 Oct;18(5):311-21 [18455428.001]
  • [Cites] Breast Cancer Res Treat. 2009 Jan;113(2):211-3 [18264757.001]
  • [Cites] Trends Mol Med. 2009 Jan;15(1):5-13 [19091631.001]
  • [Cites] Hepatology. 2000 Jan;31(1):235-40 [10613752.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):992-1001 [10713682.001]
  • [Cites] Melanoma Res. 2000 Dec;10(6):507-14 [11198471.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8298-305 [11719463.001]
  • [Cites] Nat Med. 2002 Sep;8(9):1011-7 [12195435.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):498-505 [12492492.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):537-46 [12492495.001]
  • [Cites] Nature. 2003 Apr 24;422(6934):897-901 [12665832.001]
  • [Cites] J Pathol. 2003 Jul;200(4):429-47 [12845611.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):2113-26 [14578209.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3483-93 [12893756.001]
  • [Cites] Birth Defects Res C Embryo Today. 2003 Aug;69(3):209-18 [14671774.001]
  • [Cites] Lab Invest. 2004 Feb;84(2):245-52 [14688799.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5973-81 [15342376.001]
  • [Cites] Cancer. 1974 Oct;34(4 Suppl):suppl:1488-503 [4608683.001]
  • [Cites] Mol Cell Biol. 1983 Apr;3(4):523-38 [6687920.001]
  • [Cites] Cancer Metastasis Rev. 1984;3(3):193-222 [6388823.001]
  • [Cites] Cancer Res. 1989 Nov 1;49(21):6085-90 [2477151.001]
  • [Cites] EMBO J. 1994 Dec 1;13(23):5570-80 [7988554.001]
  • [Cites] Toxicol Pathol. 1996 Nov-Dec;24(6):710-6 [8994298.001]
  • [Cites] N Engl J Med. 1997 Mar 27;336(13):897-904 [9070469.001]
  • [Cites] Bone Marrow Transplant. 2004 Dec;34(11):981-5 [15502854.001]
  • (PMID = 19816927.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 1-R01-CA112481; United States / NIA NIH HHS / AG / R01 AG023510; United States / NCI NIH HHS / CA / R01 CA112481; United States / NCI NIH HHS / CA / R01 CA112481-05; United States / NIA NIH HHS / AG / 1-R01-AG023510
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS163514; NLM/ PMC3051419
  •  go-up   go-down


63. Okines AF, Cunningham D: Trastuzumab in gastric cancer. Eur J Cancer; 2010 Jul;46(11):1949-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Trastuzumab is a fully humanised monoclonal antibody directed at the human epidermal growth factor receptor-2 (HER-2) which has been a component of standard therapy for advanced and resected HER-2-positive breast cancers for almost a decade.
  • HER-2 over-expression, defined as HER-2 protein over-expression using immunohistochemistry scored as 3+ and/or erbB-2 amplification detected by fluorescent in situ hybridisation, was detected in 22.1% of 3807 patients with advanced gastric and oesophagogastric junction (OGJ) adenocarcinoma screened for eligibility for the phase III ToGA study.
  • The validated scoring system for HER-2 positivity in gastric cancers differs from that recommended for breast cancer due to an increased frequency of incomplete membranous immunoreactivity and heterogeneity of HER-2 expression in gastric cancers.
  • The international multicentre randomised phase III ToGA study assessed the addition of trastuzumab to a cisplatin plus fluoropyrimidine (FP) chemotherapy doublet for patients with HER-2-positive advanced gastric or OGJ adenocarcinoma.
  • Additionally, research into mechanisms of resistance and strategies to overcome primary or acquired resistance to trastuzumab must now be expedited, using lessons learnt over the past decade in HER-2-positive breast cancer to maximise the benefit from this agent.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20542421.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Quinazolines; 0VUA21238F / lapatinib; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


64. Hicks DG, Yoder BJ, Pettay J, Swain E, Tarr S, Hartke M, Skacel M, Crowe JP, Budd GT, Tubbs RR: The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study. Hum Pathol; 2005 Apr;36(4):348-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study.
  • Clinical and in vitro evidence supports the concept that human epidermal growth factor receptor-2 ( HER2 ) gene amplification prediction of response to anthracycline-based chemotherapy in breast cancer is not a direct effect of HER2 overexpression, but the result of coamplification of topoisomerase II-alpha ( TOP2A ).
  • We investigated the relationship of TOP2A to HER2 genomic alterations by fluorescence in situ hybridization (FISH) and the correlations with polysomic states for chromosome 17 (CEP17).
  • One hundred thirty-eight cases of breast cancer HER2 gene amplified by 2-color FISH ( HER2 /CEP17) were reevaluated with a 3-color probe set ( HER2 /CEP17/ TOP2A ) to investigate the frequency of coamplification and deletion of TOP2A .
  • The current study demonstrates the complex interrelationship between the HER2 and TOP2A genes in breast cancer.
  • The clinical implications of TOP2A amplification and deletion in breast cancer need to be further defined.
  • [MeSH-major] Adenocarcinoma / genetics. Antigens, Neoplasm / genetics. Breast Neoplasms / genetics. Chromosomes, Human, Pair 17. DNA Topoisomerases, Type II / genetics. DNA-Binding Proteins / genetics. Genes, erbB-2
  • [MeSH-minor] Aneuploidy. Chromosome Deletion. Female. Gene Dosage. Humans. In Situ Hybridization, Fluorescence. Middle Aged


65. Sato T, Muto I, Fushiki M, Hasegawa M, Hasegawa M, Sakai T, Sekiya M: Metastatic breast cancer from gastric and ovarian cancer, mimicking inflammatory breast cancer: report of two cases. Breast Cancer; 2008;15(4):315-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic breast cancer from gastric and ovarian cancer, mimicking inflammatory breast cancer: report of two cases.
  • Breast metastases from extra-mammary malignancies, especially those mimicking primary inflammatory breast carcinoma, are extremely rare.
  • We report here two cases of inflammatory breast metastases from gastric or ovarian cancer.
  • Both patients, who had prior advanced malignant disease, presented with unilateral breast redness and swelling with peau d'orange sign, resembling primary inflammatory breast cancer or acute mastitis.
  • Breast biopsy revealed poorly differentiated adenocarcinoma with signet-ring cells or clear cell carcinoma in the lymphatic vessels and the parenchyma without an in situ lesion, similar to primary lesions of the stomach or ovary, respectively.
  • Immunohistochemical staining for estrogen receptor, progesterone receptor, and gross cystic disease fluid protein 15 was of value for correct diagnosis.
  • Since breast metastasis is a sign of poor prognosis of the primary malignant disease, the possibility of breast metastasis should be considered in appropriate patients to preclude unnecessary major surgery.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / secondary. Ovarian Neoplasms / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Clear Cell / therapy. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Tomography, X-Ray Computed


66. Lee JW, Soung YH, Seo SH, Kim SY, Park CH, Wang YP, Park K, Nam SW, Park WS, Kim SH, Lee JY, Yoo NJ, Lee SH: Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res; 2006 Jan 1;12(1):57-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.
  • PURPOSE: Recent reports revealed that the kinase domain of the ERBB2 gene is somatically mutated in lung adenocarcinoma, suggesting the mutated ERBB2 gene as an oncogene in human cancers.
  • EXPERIMENTAL DESIGN: Here, we did a mutational analysis of the ERBB2 kinase domain by PCR single-strand conformational polymorphism assay in gastric, colorectal, and breast carcinoma tissues.
  • RESULTS: We detected the ERBB2 kinase domain mutations in 9 of 180 gastric carcinomas (5.0%), in 3 of 104 colorectal carcinomas (2.9%), and in 4 of 94 breast carcinomas (4.3%).
  • CONCLUSION: This study showed that in addition to lung adenocarcinomas, ERBB2 kinase domain mutation occurs in other common human cancers such as gastric, breast, and colorectal cancers, and suggested that alterations of ERBB2-mediated signaling pathway by ERBB2 mutations alone or together with K-RAS mutations may contribute to the development of human cancers.
  • [MeSH-major] Breast Neoplasms / genetics. Colorectal Neoplasms / genetics. Genes, erbB-2 / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Aged. DNA Mutational Analysis. Female. Genes, ras / genetics. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mutation. Phosphatidylinositol 3-Kinases / genetics. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Proto-Oncogene Proteins B-raf / genetics. Receptor, Epidermal Growth Factor / genetics


67. Onuma K, Dabbs DJ, Bhargava R: Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium. Int J Gynecol Pathol; 2008 Jul;27(3):418-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mammaglobin (MGB), a secretory protein belonging to the uteroglobin/Clara cell protein family, is a sensitive marker for breast carcinoma, but is also reported to be expressed in the female genital tract and its neoplasms.
  • To investigate the potential use of MGB in gynecologic pathology practice, we tested MGB expression by immunohistochemistry on 47 endocervical adenocarcinomas (whole tissue sections of 13 invasive and 35 in situ) and 55 endometrial carcinomas (39 endometrioid and 16 nonendometrioid represented on a single tissue microarray).
  • Endocervical adenocarcinoma in situ (AIS) showed either weak (predominantly) or moderate (occasionally) expression in about 40% of the cases in comparison with strong positivity in benign endocervical glandular epithelium.
  • These results confirm that MGB is not specific for breast carcinoma, but is also variably expressed in nonneoplastic and neoplastic endocervical and endometrial tissues.
  • Frequent MGB expression in endometrioid endometrial adenocarcinoma is significantly different from nonendometrioid carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Carcinoma in Situ / metabolism. Neoplasm Proteins / biosynthesis. Uterine Neoplasms / metabolism. Uteroglobin / biosynthesis. Uterus / metabolism

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580321.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


68. Rossi E, Villanacci V, Bassotti G, Donato F, Festa A, Cengia G, Grisanti S, Cestari R: TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma. Histopathology; 2010 Jul;57(1):81-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma.
  • AIMS: Topoisomerase IIalpha (TOPOIIalpha) and HER-2/neu are chromosome 17q genes coamplified in various cancers; no data exist for Barrett's oesophagus (BO) and BO adenocarcinoma (ADC).
  • METHODS AND RESULTS: Forty-four patients [18 BO, 13 BO with dysplasia (five low-grade dysplasia, eight high-grade dysplasia) and 13 ADC in BO] were evaluated by immunohistochemistry and fluorescence in situ hybridization (FISH).
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Antigens, Neoplasm / genetics. Barrett Esophagus / genetics. Barrett Esophagus / pathology. DNA Topoisomerases, Type II / genetics. DNA-Binding Proteins / genetics. Esophageal Neoplasms / genetics. Esophageal Neoplasms / pathology. Genes, erbB-2
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aneuploidy. Chromosomes, Human, Pair 17 / genetics. Diagnosis, Differential. Female. Gene Amplification. Gene Expression. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Receptor, ErbB-2 / metabolism. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neoplasma. 2006;53(5):393-401 [17013533.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2893-8 [17363613.001]
  • [Cites] Dig Liver Dis. 2007 Apr;39(4):305-11 [17307036.001]
  • [Cites] Mod Pathol. 2007 May;20(5):584-91 [17396141.001]
  • [Cites] J Clin Pathol. 2007 Jul;60(7):768-72 [16882699.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5115-23 [17785566.001]
  • [Cites] Hum Pathol. 2008 Mar;39(3):403-9 [18261624.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6440-8 [18927283.001]
  • [Cites] Minerva Gastroenterol Dietol. 2008 Dec;54(4):347-53 [19047975.001]
  • [Cites] J Cell Mol Med. 2009 Sep;13(9B):3826-33 [19292734.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):35-9 [10665910.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):839-47 [10702400.001]
  • [Cites] Anal Cell Pathol. 2000;20(1):25-32 [11007435.001]
  • [Cites] J Natl Cancer Inst. 2000 Dec 20;92(24):1991-8 [11121461.001]
  • [Cites] J Clin Pathol. 2000 Dec;53(12):890-2 [11265171.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1061-7 [11948114.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1107-16 [12006526.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3857-62 [12473600.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):676-84 [12951586.001]
  • [Cites] Clin Breast Cancer. 2003 Aug;4(3):179-86 [14499010.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Apr;39(4):288-97 [14978790.001]
  • [Cites] J Clin Pathol. 2004 Mar;57(3):233-7 [14990588.001]
  • [Cites] Neoplasma. 2004;51(3):193-7 [15254672.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):11-6 [15261138.001]
  • [Cites] Genes Chromosomes Cancer. 1990 May;2(1):63-70 [1980607.001]
  • [Cites] Anticancer Drugs. 1995 Apr;6(2):195-211 [7795268.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):761-8 [9284825.001]
  • [Cites] Hum Pathol. 1997 Oct;28(10):1180-8 [9343325.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 16;90(18):1346-60 [9747866.001]
  • [Cites] Stem Cells. 1998;16(6):413-28 [9831867.001]
  • [Cites] Am J Clin Pathol. 2005 Jan;123(1):28-35 [15762277.001]
  • [Cites] Hum Pathol. 2005 Apr;36(4):348-56 [15891995.001]
  • [Cites] Ann Surg Oncol. 2006 Jan;13(1):12-30 [16378161.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):69-83 [16514135.001]
  • [Cites] Hum Pathol. 2006 Oct;37(10):1333-43 [16949920.001]
  • (PMID = 20557373.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2916224
  •  go-up   go-down


69. Abdel-Fatah TM, Powe DG, Hodi Z, Reis-Filho JS, Lee AH, Ellis IO: Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol; 2008 Apr;32(4):513-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family.
  • We have previously provided evidence showing an association between some precursor lesions with low nuclear grade breast carcinomas (LNGBCs).
  • Precursor lesions including columnar cell lesions, atypical ductal hyperplasia, ductal carcinoma in situ, usual epithelial hyperplasia, and lobular neoplasia were compared with matching "morphologically normal" terminal lobular duct units and matching invasive carcinoma.
  • The epithelial cells in the putative precursor flat epithelial atypia, atypical ductal hyperplasia, lobular neoplasia, ductal carcinoma in situ lesions, and their coexisting LNGBC were negative for basal and myoepithelial markers, but positive for CK19/18/8, estrogen receptor (ER)-alpha, Bcl-2, and cyclin D1.
  • The ER-alpha/ER-beta expression ratio increased during carcinogenesis, as did expression of cyclin D1 and Bcl-2. p53 immunopositivity was found 3% in LNGBC versus 43% in high nuclear grade breast carcinoma (HNGBC), whereas ataxia telangiectasia mutated expression was absent or reduced in 22% of LNGBC versus 53% of HNGBC cases.
  • These may represent a family of precursor, in situ and invasive neoplastic lesions belonging to the luminal "A" subclass of breast cancer.
  • Ataxia telangiectasia mutated may be one of the alternative regulatory mechanisms to TP53 mutation or dysfunction in low-grade and high-grade breast carcinoma.
  • [MeSH-major] Breast Neoplasms / chemistry. Breast Neoplasms / pathology. Mammary Glands, Human / chemistry. Mammary Glands, Human / pathology. Precancerous Conditions / chemistry. Precancerous Conditions / pathology
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / pathology. Ataxia Telangiectasia Mutated Proteins. Carcinoma, Intraductal, Noninfiltrating / chemistry. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / chemistry. Carcinoma, Lobular / pathology. Cell Cycle Proteins / analysis. Cyclin D. Cyclins / analysis. DNA-Binding Proteins / analysis. Estrogen Receptor alpha / analysis. Estrogen Receptor beta / analysis. Evolution, Molecular. Female. Humans. Hyperplasia. Immunohistochemistry. Keratin-18 / analysis. Keratin-19 / analysis. Keratin-8 / analysis. Neoplasm Invasiveness. Neoplasm Staging. Phenotype. Protein-Serine-Threonine Kinases / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Tissue Array Analysis. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Proteins / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18223478.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Cyclin D; 0 / Cyclins; 0 / DNA-Binding Proteins; 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / KRT18 protein, human; 0 / KRT8 protein, human; 0 / Keratin-18; 0 / Keratin-19; 0 / Keratin-8; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


70. Stuckey A, Dizon D, Scalia Wilbur J, Kent J, Tejada-Berges T, Gass J, Legare R: Clinical characteristics and choices regarding risk-reducing surgery in BRCA mutation carriers. Gynecol Obstet Invest; 2010;69(4):270-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: BRCA mutation carriers have a high lifetime risk of developing breast and ovarian malignancies.
  • They were more likely to be a BRCA2 mutation carrier, parous, married, employed, and had a prior history of breast cancer.
  • Pathology was typically benign; however, 15% showed ductal carcinoma in situ of the breast, 8% reported infiltrating ductal carcinoma of the breast, 3% was adenocarcinoma of the fallopian tube, and 3% was adenocarcinoma of the ovary.
  • [MeSH-major] BRCA1 Protein / genetics. BRCA2 Protein / genetics. Breast Neoplasms / prevention & control. Mutation. Ovarian Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 S. Karger AG, Basel.
  • (PMID = 20090358.001).
  • [ISSN] 1423-002X
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BLID protein, human; 0 / BRCA1 Protein; 0 / BRCA1 protein, human; 0 / BRCA2 Protein; 0 / BRCA2 protein, human
  •  go-up   go-down


71. Sitterding SM, Wiseman WR, Schiller CL, Luan C, Chen F, Moyano JV, Watkin WG, Wiley EL, Cryns VL, Diaz LK: AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas. Ann Diagn Pathol; 2008 Feb;12(1):33-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas.
  • Basal-like tumors are a newly recognized estrogen receptor (ER) negative and HER2 negative breast cancer subtype that express basal epithelial genes and are associated with poor survival.
  • The current study examined the rates and patterns of alphaB-crystallin expression in whole tissue sections of human breast, including normal tissue, proliferative lesions, in situ and invasive carcinomas (ER positive, HER2 positive, basal-like, and metaplastic cancers).
  • In normal breast tissue, proliferative lesions and in situ carcinomas, alphaB-crystallin expression was restricted to the myoepithelial cell compartment of ductal and lobular units.
  • Conversely, no staining for alphaB-crystallin was observed in nonbasal-like (ie, ER positive or HER2 positive) breast carcinomas.
  • Taken together, our results indicate that alphaB-crystallin is a sensitive (81%) and specific (100%) marker for basal-like breast carcinomas.
  • Moreover, the high rates of expression of alphaB-crystallin in metaplastic breast carcinomas (86%) suggest that these tumors may represent a histologically distinctive subset of basal-like breast tumors with a similar underlying molecular etiology.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Neoplasm Proteins / metabolism. alpha-Crystallin B Chain / metabolism
  • [MeSH-minor] Breast Cyst / metabolism. Breast Cyst / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Cell Proliferation. Female. Fibrocystic Breast Disease / metabolism. Fibrocystic Breast Disease / pathology. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Metaplasia. Neoplasm Invasiveness. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18164413.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA89018; United States / NCI NIH HHS / CA / R01CA097198
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / alpha-Crystallin B Chain
  •  go-up   go-down


72. Liu M, Chen W, Li XR, Li JL, Wang JD, Zhang YJ, Zheng YQ, Wei LX: [Study on diagnostic accuracy of ultrasound-guided core needle breast biopsy]. Zhonghua Bing Li Xue Za Zhi; 2010 Nov;39(11):739-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on diagnostic accuracy of ultrasound-guided core needle breast biopsy].
  • OBJECTIVE: to evaluate the diagnostic accuracy of ultrasound-guided core needle biopsy of breast tumors.
  • METHODS: six hundred and sixty-seven cases of core needle biopsy of breast encountered during the period from January, 2004 to June, 2007 were retrieved from the archival file and retrospectively reviewed.
  • RESULTS: three hundred and eighty-two patients had core needle biopsy diagnosis followed by local excision, breast conservation surgery or mastectomy.
  • The rate of underestimation for ductal carcinoma-in-situ was 6/11.
  • CONCLUSION: in order to improve the diagnostic accuracy of core needle biopsy of breast tumors, recognition of the limitation of the procedure, application of immunohistochemistry and awareness of potentially rare entities are important.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Mucinous / ultrasonography. Antigens, CD56 / metabolism. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / surgery. Carcinoma, Intraductal, Noninfiltrating / ultrasonography. False Negative Reactions. Female. Humans. Keratin-5 / metabolism. Mastectomy / methods. Membrane Proteins / metabolism. Retrospective Studies. Ultrasonography, Interventional / methods. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21215163.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / CKAP4 protein, human; 0 / Keratin-5; 0 / Membrane Proteins
  •  go-up   go-down


73. Chung AC, Zhou S, Liao L, Tien JC, Greenberg NM, Xu J: Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice. Cancer Res; 2007 Jun 15;67(12):5965-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice.
  • Although the amplified-in-breast cancer 1 (AIB1; SRC-3, ACTR, or NCoA3) was defined as a coactivator for androgen receptor (AR) by in vitro studies, its role in AR-mediated prostate development and prostate cancer remained unexplored.
  • Surprisingly, when prostate tumorigenesis was induced by the SV40 transgene in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice, AIB1 expression was observed in certain epithelial cells of the prostate intraepithelial neoplasia (PIN) and well-differentiated carcinoma and in almost all cells of the poorly differentiated carcinoma.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Sci (Lond). 2005 Apr;108(4):293-308 [15603554.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2111-22 [15788656.001]
  • [Cites] J Biol Chem. 2005 Jul 1;280(26):25134-45 [15802273.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7976-83 [16140970.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7993-8002 [16140972.001]
  • [Cites] J Clin Oncol. 2005 Nov 10;23(32):8146-51 [16278465.001]
  • [Cites] Acta Pharmacol Sin. 2006 Apr;27(4):387-94 [16539836.001]
  • [Cites] Mol Cell Biol. 2006 May;26(10):3810-23 [16648476.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16716-21 [17065319.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(12):5157-71 [15169882.001]
  • [Cites] J Biol Chem. 2004 Jul 23;279(30):31105-12 [15145939.001]
  • [Cites] Prostate. 2004 Oct 1;61(2):142-52 [15305337.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):263-74 [15380517.001]
  • [Cites] Biol Reprod. 1986 Jun;34(5):961-71 [3730488.001]
  • [Cites] Biol Reprod. 1986 Jun;34(5):973-83 [3730489.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4096-102 [8797572.001]
  • [Cites] Nature. 1997 Jun 12;387(6634):677-84 [9192892.001]
  • [Cites] Science. 1997 Aug 15;277(5328):965-8 [9252329.001]
  • [Cites] Clin Cancer Res. 1998 Dec;4(12):2925-9 [9865902.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):525-36 [10027410.001]
  • [Cites] Urology. 1999 Apr;53(4):707-13 [10197845.001]
  • [Cites] J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):3-12 [10418975.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7727-37 [15570007.001]
  • [Cites] Clin Sci (Lond). 2005 Jan;108(1):1-11 [15384949.001]
  • [Cites] Mol Endocrinol. 2006 Dec;20(12):3105-19 [16916939.001]
  • [Cites] Mol Endocrinol. 1999 Nov;13(11):1924-33 [10551785.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6379-84 [10823921.001]
  • [Cites] Int J Cancer. 2000 May 20;89(3):217-23 [10861496.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3650-4 [10910081.001]
  • [Cites] FEBS Lett. 2000 Nov 24;485(2-3):195-9 [11094166.001]
  • [Cites] Horm Metab Res. 2001 Mar;33(3):121-6 [11355743.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jul;68(1):21-8 [11678305.001]
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):1928-36 [11747336.001]
  • [Cites] Differentiation. 2001 Oct;68(4-5):270-9 [11776479.001]
  • [Cites] Cell. 2002 Feb 22;108(4):465-74 [11909518.001]
  • [Cites] Mol Cell Biol. 2002 May;22(10):3549-61 [11971985.001]
  • [Cites] Circulation. 2002 Jun 4;105(22):2653-9 [12045172.001]
  • [Cites] Cancer. 2002 Dec 1;95(11):2346-52 [12436441.001]
  • [Cites] J Neurosci. 2003 Jan 1;23(1):213-22 [12514218.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2226-30 [12589022.001]
  • [Cites] J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):3-14 [12650696.001]
  • [Cites] N Engl J Med. 2003 Jul 24;349(4):366-81 [12878745.001]
  • [Cites] Mol Endocrinol. 2003 Sep;17(9):1681-92 [12805412.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(21):7742-55 [14560019.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1875-85 [14996752.001]
  • [Cites] J Biol Chem. 2004 Apr 9;279(15):14909-16 [14747462.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3334-43 [15126378.001]
  • [Cites] Prostate. 2003 May 15;55(3):219-37 [12692788.001]
  • (PMID = 17575167.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK58242; United States / NIDDK NIH HHS / DK / DK058242-05; United States / NCI NIH HHS / CA / CA119689-03; United States / NCI NIH HHS / CA / CA112403; United States / NCI NIH HHS / CA / R01 CA112403-02; United States / NCI NIH HHS / CA / CA112403-02; United States / NIDDK NIH HHS / DK / R01 DK058242-05; United States / NCI NIH HHS / CA / R01 CA119689-03; United States / NCI NIH HHS / CA / CA119689; United States / NCI NIH HHS / CA / R01 CA112403; United States / NIDDK NIH HHS / DK / R01 DK058242; United States / NCI NIH HHS / CA / R01 CA119689
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Androgen; 0 / Trans-Activators; EC 2.3.1.48 / Histone Acetyltransferases; EC 2.3.1.48 / Ncoa3 protein, mouse; EC 2.3.1.48 / Nuclear Receptor Coactivator 3
  • [Other-IDs] NLM/ NIHMS50339; NLM/ PMC2898573
  •  go-up   go-down


74. Garedew A, Kämmerer U, Singer D: Respiratory response of malignant and placental cells to changes in oxygen concentration. Respir Physiol Neurobiol; 2009 Feb 28;165(2-3):154-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant cells and foetal tissues are exposed to low oxygen partial pressure (pO2) in situ due to the limited supply of oxygenated blood.
  • [MeSH-major] Breast Neoplasms / metabolism. Leukocytes / metabolism. Oxygen / pharmacology. Oxygen Consumption / physiology. Placenta / cytology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cell Hypoxia / physiology. Cell Line, Tumor. Cell Respiration / physiology. Endothelial Cells / cytology. Endothelial Cells / metabolism. Female. Fetus / cytology. Humans. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Umbilical Veins / cytology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19041734.001).
  • [ISSN] 1569-9048
  • [Journal-full-title] Respiratory physiology & neurobiology
  • [ISO-abbreviation] Respir Physiol Neurobiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


75. Shaik MS, Chatterjee A, Jackson T, Singh M: Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors. Int J Cancer; 2006 Jan 15;118(2):396-404
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors.
  • Our study investigates the effect of a highly selective cyclooxygenase-2 (COX-2) inhibitor, celecoxib, on the cytotoxicity of docetaxel in nude mice bearing A549 tumor xenografts and elucidates the molecular mechanisms of the antitumor effect of this combination.
  • Female nu/nu mice, xenografted with s.c.
  • A549 tumors were treated with either celecoxib (150 mg/kg/day), docetaxel (10 mg/kg) or a combination of both.
  • The tumor tissues were quantified for the induction of apoptosis, intratumor levels/expressions of prostaglandin E2 (PGE2), 15 deoxy prostaglandin J2 (15-d PGJ2), microsomal prostaglandin E synthase (mPGES) and cytoplasmic phospholipase A2 (cPLA2).
  • The combination of celecoxib with docetaxel significantly inhibited the tumor growth (p < 0.03) as compared to celecoxib or docetaxel alone, decreased the levels of PGE2 by 10-fold and increased the 15-d PGJ2 levels by 4-fold as compared to control.
  • The combination also enhanced the peroxisome proliferator-activated receptor (PPAR)-gamma expression, decreased the expression of cPLA2, mPGES and vascular endothelial growth factor (VEGF), but had no effect on the expression of COX-1 or COX-2 in tumor tissues.
  • TUNEL staining of the tumor tissues showed a marked increase in the apoptosis in the combination group as compared to the celecoxib- or docetaxel-treated groups and this was associated with an increase in the intratumor p53 expression.
  • In conclusion, the combination of celecoxib with docetaxel produces a greater antitumor effect in s.c.
  • A549 tumors as compared to celecoxib or docetaxel alone and this effect is associated with concomitant alterations in the intratumor levels of PGE2 and 15-d PGJ2.

  • Hazardous Substances Data Bank. CELECOXIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6045-51 [11085526.001]
  • [Cites] J Biol Chem. 2000 May 19;275(20):14838-45 [10809726.001]
  • [Cites] Biochem Biophys Res Commun. 2001 May 18;283(4):750-5 [11350047.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2669-74 [11555578.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2887-97 [11555607.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3178-85 [11595712.001]
  • [Cites] J Biol Chem. 2001 Nov 16;276(46):42737-43 [11559711.001]
  • [Cites] Int J Surg Investig. 2000;1(6):467-76 [11729854.001]
  • [Cites] Ann N Y Acad Sci. 2001 Dec;952:109-15 [11795429.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):625-31 [11830509.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):846-55 [11895918.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2029-33 [11929821.001]
  • [Cites] Int J Cancer. 2002 Apr 20;98(6):817-23 [11948457.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2443-7 [12114451.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5778-84 [12384538.001]
  • [Cites] Mol Pharmacol. 2002 Nov;62(5):1207-14 [12391285.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):2006-11 [10815926.001]
  • [Cites] J Urol. 2000 Sep;164(3 Pt 1):820-5 [10953162.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6706-11 [12438270.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):84-90 [12455057.001]
  • [Cites] Pharmacotherapy. 2003 Jan;23(1):9-28 [12523457.001]
  • [Cites] Breast Cancer Res Treat. 2003 Mar;78(1):97-103 [12611462.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1566-72 [12684433.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1885-97 [12738747.001]
  • [Cites] Mol Cancer Ther. 2003 May;2(5):479-88 [12748310.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2003 Jul;3(4):291-306 [12769774.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jul 11;306(4):887-97 [12821125.001]
  • [Cites] Regul Pept. 2003 Jul 15;114(2-3):101-7 [12832097.001]
  • [Cites] FEBS Lett. 2003 Jul 17;547(1-3):75-9 [12860389.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2645-50 [12860939.001]
  • [Cites] Pharm Res. 2003 Sep;20(9):1485-95 [14567645.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):279-85 [14729635.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):369-75 [14751505.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):1181-9 [14871855.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1369-76 [14973068.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1521-9 [14977856.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;33(6):515-22 [8137463.001]
  • [Cites] Invest New Drugs. 1995;13(1):1-11 [7499102.001]
  • [Cites] J Biol Chem. 1997 Jun 6;272(23):14501-4 [9169405.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4A):2327-38 [9703875.001]
  • [Cites] Cancer Res. 1998 Sep 1;58(17):3761-4 [9731479.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):4997-5001 [9823297.001]
  • [Cites] Clin Cancer Res. 1999 May;5(5):1001-5 [10353732.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):490-8 [15455390.001]
  • [Cites] Oncogene. 2005 Feb 24;24(9):1634-40 [15608668.001]
  • [Cites] Pharm Res. 2005 Mar;22(3):427-39 [15835749.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1306-11 [10728691.001]
  • [Cites] Neoplasia. 2001 Jan-Feb;3(1):53-61 [11326316.001]
  • (PMID = 16052515.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / G12 RR003020; United States / NCRR NIH HHS / RR / RR003020-255369; United States / NCRR NIH HHS / RR / G12 RR003020-255369; United States / NCRR NIH HHS / RR / RR003020-200011; United States / NCRR NIH HHS / RR / G12 RR003020-200011
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 0 / Pyrazoles; 0 / Sulfonamides; JCX84Q7J1L / Celecoxib; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ NIHMS214120; NLM/ PMC2907249
  •  go-up   go-down


76. Bendrik C, Dabrosin C: Estradiol increases IL-8 secretion of normal human breast tissue and breast cancer in vivo. J Immunol; 2009 Jan 1;182(1):371-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estradiol increases IL-8 secretion of normal human breast tissue and breast cancer in vivo.
  • IL-8 or CXCL8 has been associated with tumor angiogenesis, metastasis, and poor prognosis in breast cancer.
  • Estrogen is crucial in breast carcinogenesis and tumor progression.
  • Whether sex steroids affect IL-8 secretion of normal breast tissue or breast cancer is not known.
  • We used microdialysis to sample IL-8 in normal human breast tissue in situ in pre- and postmenopausal women, preoperatively in breast cancers of women, and in experimental breast cancer in mice.
  • We found a significant positive correlation between IL-8 and estradiol in normal breast tissue and hormone-dependent breast cancer in vivo.
  • Ex vivo, estradiol exposure increased the IL-8 secretion of normal whole breast tissue in culture.
  • In experimental breast cancer, estradiol increased IL-8 whereas the anti-estrogen tamoxifen inhibited the secretion of IL-8 both in vitro and extracellularly in vivo in tumors of nude mice.
  • Our results strongly suggest that estradiol has a critical role in the regulation of IL-8 in normal human breast tissue and human breast cancer.
  • IL-8 may present a novel therapeutic target for estrogen driven breast carcinogenesis and tumor progression.
  • [MeSH-major] Adenocarcinoma / secretion. Breast / immunology. Breast / secretion. Breast Neoplasms / secretion. Estradiol / physiology. Interleukin-8 / secretion. Up-Regulation / immunology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19109168.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-8; 4TI98Z838E / Estradiol
  •  go-up   go-down


77. Hicks DG, Kulkarni S: HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol; 2008 Feb;129(2):263-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools.
  • Clinical laboratory testing for human epidermal growth factor receptor 2 (HER2) status in newly diagnosed breast cancer is critically important for therapeutic decision making.
  • Unlike most pathologic testing, which serves as an adjunct to establishing a diagnosis, the results of HER2 testing stand alone in determining which patients are likely to respond to trastuzumab, a monoclonal antibody against HER2.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Breast Neoplasms / diagnosis. Breast Neoplasms / genetics. Genes, erbB-2
  • [MeSH-minor] Algorithms. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Guidelines as Topic. Humans. Immunohistochemistry / standards. In Situ Hybridization, Fluorescence / standards. Laboratories / standards. Quality Control. Sensitivity and Specificity. Trastuzumab

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Clin Pathol. 2009 Jun;131(6):897-8; author reply 898-900 [19461099.001]
  • (PMID = 18208807.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; P188ANX8CK / Trastuzumab
  • [Number-of-references] 62
  •  go-up   go-down


78. Belguise K, Guo S, Yang S, Rogers AE, Seldin DC, Sherr DH, Sonenshein GE: Green tea polyphenols reverse cooperation between c-Rel and CK2 that induces the aryl hydrocarbon receptor, slug, and an invasive phenotype. Cancer Res; 2007 Dec 15;67(24):11742-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Exposure to and bioaccumulation of lipophilic environmental pollutants, such as polycyclic aromatic hydrocarbons (PAHs), has been implicated in breast cancer.
  • Here, we show that green tea prevents or reverses loss of the epithelial marker E-cadherin on the surface of DMBA-induced in situ cancers.
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene. Adenocarcinoma / chemically induced. Adenocarcinoma / genetics. Adenocarcinoma / pathology. Animals. Beverages. Carcinoma in Situ / chemically induced. Carcinoma in Situ / genetics. Carcinoma in Situ / pathology. Female. Neoplasm Invasiveness / genetics. Phenotype. Polyphenols. Rats. Rats, Sprague-Dawley

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089804.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA71796; United States / NIEHS NIH HHS / ES / P01 ES11624
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols; 0 / Proto-Oncogene Proteins c-rel; 0 / Transcription Factors; 0 / snail family transcription factors; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; EC 2.7.11.1 / Casein Kinase II
  •  go-up   go-down


79. Mendes O, Kim HT, Stoica G: Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model. Clin Exp Metastasis; 2005;22(3):237-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model.
  • In order to study the expression of MMP2, MMP3 and MMP9 in breast cancer brain metastasis, we used a syngeneic rat model of distant metastasis of ENU1564, a carcinogen-induced mammary adenocarcinoma cell line.
  • In situ zymography revealed gelatinase activity within the brain metastasis.
  • Furthermore, we were able to significantly decrease the development of breast cancer brain metastasis in animals by treatment with PD 166793, a selective synthetic MMP inhibitor.
  • Together our results suggest that MMP-2, -3 and -9 may be involved in the process of metastasis of breast cancer to the brain.
  • [MeSH-major] Adenocarcinoma / metabolism. Brain Neoplasms / metabolism. Breast Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Matrix Metalloproteinase 2 / genetics. Matrix Metalloproteinase 3 / genetics. Matrix Metalloproteinase 9 / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cancer Res Clin Oncol. 2005 Mar;131(3):191-8 [15592684.001]
  • [Cites] Eur J Neurosci. 2002 Jan;15(1):19-32 [11860503.001]
  • [Cites] Bioessays. 1992 Mar;14(3):185-94 [1586372.001]
  • [Cites] J Mol Cell Cardiol. 2003 May;35(5):539-48 [12738235.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jan;65(1):55-61 [11245340.001]
  • [Cites] J Surg Res. 2003 Apr;110(2):383-92 [12788669.001]
  • [Cites] Acta Neurochir (Wien). 2003 Sep;145(9):825-38 [14505115.001]
  • [Cites] Genes Dev. 1999 Jan 1;13(1):35-48 [9887098.001]
  • [Cites] Cell. 2003 Jun 27;113(7):821-3 [12837240.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1320-6 [11245428.001]
  • [Cites] Breast Cancer Res Treat. 2000 Sep;63(2):105-15 [11097087.001]
  • [Cites] Clin Exp Metastasis. 2000;18(2):171-8 [11235993.001]
  • [Cites] J Orthop Sci. 2000;5(1):75-81 [10664443.001]
  • [Cites] Vet Pathol. 2003 May;40(3):227-36 [12724562.001]
  • [Cites] Clin Exp Metastasis. 1995 Mar;13(2):67-88 [7882617.001]
  • [Cites] Virchows Arch. 1999 Dec;435(6):566-73 [10628798.001]
  • [Cites] Circulation. 2002 Apr 23;105(16):1983-8 [11997287.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):652-8 [14744781.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6758-62 [14583471.001]
  • [Cites] J Neurosci. 2003 May 15;23(10):4034-43 [12764090.001]
  • [Cites] Br J Cancer. 2003 Apr 22;88(8):1318-26 [12698202.001]
  • [Cites] Oncogene. 1997 Jun 12;14(23):2767-74 [9190892.001]
  • [Cites] Glia. 2003 Sep;43(3):254-64 [12898704.001]
  • [Cites] Clin Exp Metastasis. 2003;20(5):407-12 [14524529.001]
  • [Cites] Eur J Cancer. 2003 Jul;39(11):1632-41 [12855272.001]
  • [Cites] Int J Oncol. 2002 Jul;21(1):25-30 [12063545.001]
  • [Cites] Brain Res. 2001 Mar 2;893(1-2):104-12 [11222998.001]
  • [Cites] J Pathol. 1999 Oct;189(2):161-8 [10547569.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1998 Apr;3(2):177-89 [10819526.001]
  • [Cites] Annu Rev Cell Biol. 1993;9:541-73 [8280471.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):1057-63 [14871985.001]
  • [Cites] Tumour Biol. 2003 Sep-Oct;24(5):258-70 [15001838.001]
  • [Cites] J Med Chem. 2000 Jan 27;43(2):156-66 [10649971.001]
  • [Cites] J Histochem Cytochem. 1999 Dec;47(12):1575-80 [10567441.001]
  • [Cites] Am J Pathol. 1996 Jul;149(1):273-82 [8686751.001]
  • [Cites] Br J Cancer. 2000 Dec;83(11):1538-43 [11076665.001]
  • [Cites] FEBS Lett. 2003 Oct 23;553(3):457-63 [14572669.001]
  • [Cites] Cancer Lett. 2004 Oct 28;214(2):205-13 [15363547.001]
  • [Cites] Anticancer Res. 1999 Sep-Oct;19(5B):4257-64 [10628384.001]
  • [Cites] Clin Exp Metastasis. 1994 Jul;12(4):283-95 [8039303.001]
  • [Cites] Endocrinology. 2000 Oct;141(10):3764-73 [11014232.001]
  • [Cites] Brain Res Mol Brain Res. 2002 Apr 30;100(1-2):103-17 [12008026.001]
  • [Cites] Lab Invest. 1997 Oct;77(4):357-68 [9354770.001]
  • [Cites] Melanoma Res. 1996 Oct;6(5):363-71 [8908596.001]
  • [Cites] Breast Cancer. 2002;9(1):26-32 [12196718.001]
  • [Cites] Breast Cancer Res. 2000;2(4):252-7 [11250717.001]
  • [Cites] Pathol Int. 2002 Apr;52(4):255-64 [12031080.001]
  • [Cites] Br J Cancer. 2004 Apr 5;90(7):1414-21 [15054465.001]
  • (PMID = 16158251.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01-NS046214-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / (R)-2-(4'-bromo-biphenyl-4-sulfonyl-amino)-3-methyl-butyric acid; 0 / Hydroxamic Acids; 0 / Oligopeptides; 0 / RNA, Messenger; EC 3.4.24.17 / Matrix Metalloproteinase 3; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


80. Wei B, Bu H, Chen HJ, Zhang HY, Li XJ: [Clinicopathologic study of solid papillary carcinoma of breast]. Zhonghua Bing Li Xue Za Zhi; 2006 Oct;35(10):589-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study of solid papillary carcinoma of breast].
  • OBJECTIVE: To study the clinicopathologic features and immunophenotype of solid papillary carcinoma (SPC) of breast.
  • Seven cases contained foci of invasive carcinoma which showed similar cytologic features as those of the in-situ component.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Papillary / pathology
  • [MeSH-minor] Actins / metabolism. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / surgery. Chromogranin A / metabolism. Female. Follow-Up Studies. Humans. Immunohistochemistry. Keratin-8 / metabolism. Mastectomy / methods. Middle Aged. Synaptophysin / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17134565.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ACTA2 protein, human; 0 / Actins; 0 / Chromogranin A; 0 / Keratin-8; 0 / Synaptophysin
  •  go-up   go-down


81. Obaidat NA, Awamleh AA, Ghazarian DM: Adenocarcinoma in situ arising in a tubulopapillary apocrine hidradenoma of the peri-anal region. Eur J Dermatol; 2006 Sep-Oct;16(5):576-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in situ arising in a tubulopapillary apocrine hidradenoma of the peri-anal region.
  • Histologically, the excised lesion showed features of tubulopapillary apocrine hidradenoma, with an area showing features of carcinoma in situ.
  • The lesion also had papillary and cribriform growth patterns, reminiscent of breast lesions.
  • To the best of our knowledge, this is the first description of a peri-anal adenocarcinoma in situ arising in a tubulopapillary apocrine hidradenoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Sweat Gland / pathology. Anus Neoplasms / pathology. Carcinoma in Situ / pathology. Sweat Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101482.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


82. Rogalska A, Szwed M, Jóźwiak Z: Aclarubicin-induced apoptosis and necrosis in cells derived from human solid tumours. Mutat Res; 2010 Jul 19;700(1-2):1-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we investigated the response of A549 (non-small cell lung-cancer), HepG2 (human hepatoma) and MCF-7 (human breast adenocarcinoma) cell lines to treatment with aclarubicin (ACL).
  • [MeSH-minor] Caspase 3 / metabolism. Caspase 8 / metabolism. DNA Fragmentation / drug effects. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Humans. In Situ Nick-End Labeling. Poly(ADP-ribose) Polymerases. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20399885.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 74KXF8I502 / Aclarubicin; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8
  •  go-up   go-down


83. Dragun AE, Harper JL, Jenrette JM, Sinha D, Cole DJ: Predictors of cosmetic outcome following MammoSite breast brachytherapy: a single-institution experience of 100 patients with two years of follow-up. Int J Radiat Oncol Biol Phys; 2007 Jun 01;68(2):354-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of cosmetic outcome following MammoSite breast brachytherapy: a single-institution experience of 100 patients with two years of follow-up.
  • PURPOSE: To identify the factors that predict for excellent cosmesis in patients who receive MammoSite breast brachytherapy (MBT).
  • METHODS AND MATERIALS: One hundred patients with Stage 0, I, or II adenocarcinoma of the breast underwent adjuvant therapy using MBT.
  • Factors that did not predict for cosmesis were age, balloon placement technique, balloon volume, catheter days in situ, subcutaneous toxicity, and chemotherapy or hormonal therapy.
  • [MeSH-major] Brachytherapy / methods. Breast Neoplasms / radiotherapy. Carcinoma, Intraductal, Noninfiltrating / radiotherapy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17383829.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA069222
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iridium Radioisotopes
  •  go-up   go-down


84. Trastour C, Benizri E, Ettore F, Ramaioli A, Chamorey E, Pouysségur J, Berra E: HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int J Cancer; 2007 Apr 1;120(7):1451-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome.
  • The aim of our study was to evaluate the impact of HIF-1alpha and CA IX (carbonic anhydrase IX) (one of its target genes) expression on prognosis and treatment outcome of patients with breast cancer.
  • Afterwards, the immunohistochemical staining of HIF-1alpha and CA IX was evaluated in 132 invasive breast carcinomas with a 10-year follow-up, and correlated to classical clinicopathological parameters and response to adjuvant therapy.
  • Statistically significant association was found between HIF-1alpha or CA IX staining and the grade, hormonal receptors loss and the presence of carcinoma in situ.
  • Overexpression of HIF-1alpha and CA IX correlates with a poor prognosis in breast cancer.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Breast Neoplasms / metabolism. Carbonic Anhydrases / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Animals. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / metabolism. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Carcinoma, Medullary / drug therapy. Carcinoma, Medullary / metabolism. Carcinoma, Medullary / pathology. Chemotherapy, Adjuvant. Female. Humans. Immunoenzyme Techniques. Male. Mice. Mice, Nude. Middle Aged. Neoplasm Invasiveness. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17245699.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / HIF1A protein, human; 0 / Hif1a protein, mouse; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


85. Khayat AS, Guimarães AC, Calcagno DQ, Seabra AD, Lima EM, Leal MF, Faria MH, Rabenhorst SH, Assumpção PP, Demachki S, Smith MA, Burbano RR: Interrelationship between TP53 gene deletion, protein expression and chromosome 17 aneusomy in gastric adenocarcinoma. BMC Gastroenterol; 2009;9:55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interrelationship between TP53 gene deletion, protein expression and chromosome 17 aneusomy in gastric adenocarcinoma.
  • BACKGROUND: This study evaluates the existence of numerical alterations of chromosome 17 and TP53 gene deletion in gastric adenocarcinoma.
  • METHODS: Dual-color fluorescence in situ hybridization and immunostaining were performed in twenty gastric cancer samples of individuals from Northern Brazil.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Chromosomes, Human, Pair 17 / genetics. Gene Deletion. Gene Expression Regulation, Neoplastic / genetics. Stomach Neoplasms / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Aged. Alleles. Brazil. Breast Neoplasms / genetics. Breast Neoplasms / pathology. Case-Control Studies. Female. Humans. In Situ Hybridization, Fluorescence. Loss of Heterozygosity / genetics. Male. Middle Aged

  • Genetic Alliance. consumer health - Chromosome 17, Deletion.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2000 Sep;37(3):241-9 [10971700.001]
  • [Cites] Cancer Genet Cytogenet. 2009 Apr 1;190(1):1-7 [19264226.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):258-70 [12619111.001]
  • [Cites] Acta Biochim Pol. 2003;50(1):231-8 [12673364.001]
  • [Cites] Lab Invest. 2003 Sep;83(9):1311-20 [13679439.001]
  • [Cites] Anticancer Res. 2004 Jan-Feb;24(1):155-9 [15015591.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Sep;153(2):127-32 [15350302.001]
  • [Cites] Mod Pathol. 2004 Nov;17(11):1328-37 [15154013.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 May;83(9):2934-8 [3458254.001]
  • [Cites] Cancer Genet Cytogenet. 1986 Aug;22(4):295-307 [3731046.001]
  • [Cites] Cancer Genet Cytogenet. 1987 Jan;24(1):63-73 [3791173.001]
  • [Cites] Histochemistry. 1988;89(4):307-16 [3410743.001]
  • [Cites] Cancer. 1990 Aug 1;66(3):491-7 [2364362.001]
  • [Cites] Virchows Arch. 1995;426(5):447-55 [7633655.001]
  • [Cites] Int J Cancer. 1996 May 29;66(5):594-9 [8647618.001]
  • [Cites] Cancer. 1995 Sep 1;76(5):720-6 [8625172.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7081-4 [8692948.001]
  • [Cites] Am J Pathol. 1996 Nov;149(5):1575-84 [8909247.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Dec;92(2):122-9 [8976368.001]
  • [Cites] Nihon Ika Daigaku Zasshi. 1997 Feb;64(1):22-9 [9119949.001]
  • [Cites] Oncology. 1997 Mar-Apr;54(2):166-70 [9075790.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Apr 1;102(1):88-90 [9530349.001]
  • [Cites] Nature. 1998 Dec 17;396(6712):643-9 [9872311.001]
  • [Cites] Am J Phys Anthropol. 1999 Jun;109(2):175-80 [10378456.001]
  • [Cites] J Int Med Res. 1999 Mar-Apr;27(2):85-9 [10446695.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2005 Apr;40(4):467-70 [15795596.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 10;331(3):694-700 [15865924.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1759-66 [15827559.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6B):4069-74 [16309200.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Aug;169(1):45-9 [16875936.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4B):2909-14 [16886612.001]
  • [Cites] World J Gastroenterol. 2006 Oct 14;12(38):6207-11 [17036397.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3139-46 [10955795.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Aug;121(1):38-43 [10958939.001]
  • [Cites] Clin Exp Med. 2006 Oct;6(3):129-33 [17061062.001]
  • [Cites] Cancer Biol Ther. 2006 Sep;5(9):1154-60 [16855375.001]
  • [Cites] Arq Gastroenterol. 2006 Jul-Sep;43(3):247-51 [17160244.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 Jan;16(1):13-8 [18091326.001]
  • [Cites] Cancer Lett. 2008 Aug 8;266(2):99-115 [18381231.001]
  • [Cites] Lab Invest. 2000 Oct;80(10):1501-8 [11045566.001]
  • (PMID = 19619279.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC2716360
  •  go-up   go-down


86. Layfield LJ, Lewis C: In situ and invasive components of mammary adenocarcinoma: comparison of Her-2/neu status. Anal Quant Cytol Histol; 2007 Aug;29(4):239-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In situ and invasive components of mammary adenocarcinoma: comparison of Her-2/neu status.
  • OBJECTIVE: To compare the relationship between Her-2/neu in the invasive and in situ components of carcinoma.
  • STUDY DESIGN: Using immunohistochemistry, this study compares the Her-2/neu status in the in situ and invasive components of 200 cases of ductal carcinoma of the breast.
  • RESULTS: Twenty-five cases (12.5%) demonstrated a difference of 2 or more grades between the in situ and invasive components.
  • The in situ component always showed higher expression of Her-2/neu than did the invasive component when protein expression was discordant.
  • Comedo carcinoma was the in situ component in 12 of the 25 discordances in Her-2/neu expression.
  • CONCLUSION: Significant heterogeneity exists between Her-2/neu expression in the in situ component and invasive components of adenocarcinoma of the breast.
  • When discordance exists, the in situ component shows higher levels of expression.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17879632.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


87. Djidja MC, Francese S, Loadman PM, Sutton CW, Scriven P, Claude E, Snel MF, Franck J, Salzet M, Clench MR: Detergent addition to tryptic digests and ion mobility separation prior to MS/MS improves peptide yield and protein identification for in situ proteomic investigation of frozen and formalin-fixed paraffin-embedded adenocarcinoma tissue sections. Proteomics; 2009 May;9(10):2750-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detergent addition to tryptic digests and ion mobility separation prior to MS/MS improves peptide yield and protein identification for in situ proteomic investigation of frozen and formalin-fixed paraffin-embedded adenocarcinoma tissue sections.
  • MALDI-mass spectrometry imaging (MALDI-MSI) has been used here for direct visualisation and in situ characterisation of proteins in breast tumour tissue section samples.
  • Frozen MCF7 breast tumour xenograft and human formalin-fixed paraffin-embedded breast cancer tissue sections were used.
  • In situ protein identification was carried out directly from the tissue section by MALDI-MSI.
  • [MeSH-major] Adenocarcinoma / chemistry. Neoplasm Proteins / analysis. Proteomics / methods. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Trypsin / metabolism
  • [MeSH-minor] Animals. Breast Neoplasms / chemistry. Cell Line, Tumor. Detergents. Disease Models, Animal. Female. Gene Expression Regulation, Neoplastic. Humans. Mice. Mice, Inbred BALB C. Neoplasm Transplantation. Paraffin Embedding. Sensitivity and Specificity

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19405023.001).
  • [ISSN] 1615-9861
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Detergents; 0 / Neoplasm Proteins; EC 3.4.21.4 / Trypsin
  •  go-up   go-down


88. van Vlerken LE, Duan Z, Little SR, Seiden MV, Amiji MM: Augmentation of therapeutic efficacy in drug-resistant tumor models using ceramide coadministration in temporal-controlled polymer-blend nanoparticle delivery systems. AAPS J; 2010 Jun;12(2):171-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vivo studies in a resistant subcutaneous SKOV3 human ovarian and in an orthotopic MCF7 human breast adenocarcinoma xenograft showed that the PTX and CER nanoparticle combination therapy reduced the final tumor volume at least twofold over treatment with the standard PTX therapy alone.
  • The temporal-controlled nanoparticle delivery system presented in this study allows for a simultaneous delivery of PTX + CER in breast and ovarian tumor model drug, leading to a modulation of the apoptotic threshold.

  • COS Scholar Universe. author profiles.
  • NCI caNanoLab Data Portal. supplemental materials - caNanoLab samples curated from the publication .
  • Hazardous Substances Data Bank. TAXOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FASEB J. 2001 Mar;15(3):719-30 [11259390.001]
  • [Cites] Cancer Treat Rev. 2008 Nov;34(7):592-602 [18538481.001]
  • [Cites] J Clin Invest. 2002 Jul;110(1):3-8 [12093880.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):415-23 [12538495.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2002 May;2(3):387-401 [12678739.001]
  • [Cites] J Exp Ther Oncol. 2003 Jan-Feb;3(1):5-13 [12724854.001]
  • [Cites] J Med Chem. 2003 Nov 6;46(23):4805-17 [14584929.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9534-9 [15210954.001]
  • [Cites] Acta Oncol. 1992;31(2):115-23 [1622625.001]
  • [Cites] Acta Oncol. 1992;31(2):205-13 [1352455.001]
  • [Cites] J Biol Chem. 1996 Aug 9;271(32):19530-6 [8702646.001]
  • [Cites] Anticancer Res. 1998 Jan-Feb;18(1B):475-80 [9568165.001]
  • [Cites] Pharm Res. 2005 Dec;22(12):2107-14 [16254763.001]
  • [Cites] Nat Rev Drug Discov. 2006 Mar;5(3):219-34 [16518375.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Mar;59(4):477-84 [16862429.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4843-50 [17510414.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1830-8 [17557285.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):3193-203 [18483388.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):157-65 [11668492.001]
  • (PMID = 20143195.001).
  • [ISSN] 1550-7416
  • [Journal-full-title] The AAPS journal
  • [ISO-abbreviation] AAPS J
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA119617; United States / NCI NIH HHS / CA / R01-CA119617
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Ceramides; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / Polymers; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC2844507
  •  go-up   go-down


89. van Deurzen CH, Borgstein PJ, van Diest PJ: In-transit lymph node metastases in breast cancer: a possible source of local recurrence after Sentinel Node procedure. J Clin Pathol; 2008 Dec;61(12):1314-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In-transit lymph node metastases in breast cancer: a possible source of local recurrence after Sentinel Node procedure.
  • To which extent this also occurs in patients with breast cancer has not been studied yet.
  • The aim of this study was therefore to explore the occurrence of in-transit lymph node metastases in patients with breast cancer.
  • METHODS: Afferent lymph vessels to the SN identified by blue dye were removed from 17 patients with breast cancer during a regular SN procedure.
  • One of these lymph nodes showed a breast cancer macrometastasis, to be regarded as an in-transit metastasis.
  • This metastasis would normally have been left in situ.
  • CONCLUSIONS: In-transit lymph nodes associated with the afferent SN lymph vessels seem to occur in a significant proportion of patients with breast cancer.
  • These lymph nodes may contain metastases, which are a potential source of local recurrence when left in situ.
  • [MeSH-major] Breast Neoplasms / pathology. Lymphatic Metastasis. Neoplasm Recurrence, Local / etiology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Female. Humans. Lymph Node Excision. Sentinel Lymph Node Biopsy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Pathol. 2008 Dec;61(12):1233-5 [18829625.001]
  • (PMID = 18794198.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


90. He LR, Zhao HY, Li BK, Zhang LJ, Liu MZ, Kung HF, Guan XY, Bian XW, Zeng YX, Xie D: Overexpression of AIB1 negatively affects survival of surgically resected non-small-cell lung cancer patients. Ann Oncol; 2010 Aug;21(8):1675-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The amplified in breast cancer 1 (AIB1) gene has been considered to play an oncogenic role in human cancers, but its clinical/prognostic significance in non-small-cell lung cancer (NSCLC) is still unclear.
  • A positive correlation between AIB1 overexpression and an ascending pathologic node stage in lung adenocarcinoma (ADC) was observed (P = 0.043).

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20064830.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Androgen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.3.1.48 / NCOA3 protein, human; EC 2.3.1.48 / Nuclear Receptor Coactivator 3
  •  go-up   go-down


91. Zhao CH, Li QF: Altered profiles of nuclear matrix proteins during the differentiation of human gastric mucous adenocarcinoma MGc80-3 cells. World J Gastroenterol; 2005 Aug 14;11(30):4628-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered profiles of nuclear matrix proteins during the differentiation of human gastric mucous adenocarcinoma MGc80-3 cells.
  • AIM: To find and identify specific nuclear matrix proteins associated with proliferation and differentiation of carcinoma cells, which will be potential markers for cancer diagnosis and targets in cancer therapy.
  • Spots of nuclear matrix proteins differentially expressed were excised and subjected to in situ digestion with trypsin.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Neoplasm Proteins / metabolism. Nuclear Matrix-Associated Proteins / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094700.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Nuclear Matrix-Associated Proteins
  • [Other-IDs] NLM/ PMC4615401
  •  go-up   go-down


92. Atkin GK, Daley FM, Bourne S, Glynne-Jones R, Northover JM, Wilson GD: The impact of surgically induced ischaemia on protein levels in patients undergoing rectal cancer surgery. Br J Cancer; 2006 Oct 9;95(7):928-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colorectal cancer surgery significantly impacts on intratumoral gene expression, suggesting archival specimens may not accurately reflect in situ marker levels.
  • [MeSH-major] Adenocarcinoma / surgery. Biomarkers, Tumor / metabolism. Gene Expression. Ischemia / metabolism. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2006 Jan 16;94(1):121-7 [16404365.001]
  • [Cites] Hum Pathol. 2005 Dec;36(12):1302-8 [16311124.001]
  • [Cites] Am J Med Sci. 1993 Jul;306(1):37-41 [8328508.001]
  • [Cites] Pharm World Sci. 1994 Apr 15;16(2):84-103 [7518280.001]
  • [Cites] Nucleic Acids Res. 1995 Nov 25;23(22):4649-56 [8524656.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1063-72 [10741735.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1378-84 [10778966.001]
  • [Cites] Eur J Cancer. 2000 Aug;36(13 Spec No):1649-60 [10959051.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7075-83 [11156414.001]
  • [Cites] Oncol Rep. 2001 May-Jun;8(3):497-500 [11295069.001]
  • [Cites] J Surg Res. 2001 Aug;99(2):222-7 [11469890.001]
  • [Cites] J Natl Cancer Inst. 2001 Sep 5;93(17):1337-43 [11535709.001]
  • [Cites] Cancer Treat Rev. 2002 Feb;28(1):27-47 [12027413.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(1):359-69 [12482987.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):241-50 [12525515.001]
  • [Cites] Oncol Rep. 2003 Jul-Aug;10(4):867-9 [12792736.001]
  • [Cites] Anal Biochem. 2004 May 15;328(2):101-8 [15113684.001]
  • [Cites] Breast Cancer Res. 2004;6(4):R450-9 [15217513.001]
  • [Cites] Exp Mol Pathol. 2004 Dec;77(3):222-30 [15507240.001]
  • [Cites] Biochemistry. 1974 Jan 29;13(3):471-81 [4203910.001]
  • [Cites] J Biol Chem. 1987 Mar 25;262(9):4098-103 [3549724.001]
  • [Cites] Cancer Res. 1997 Feb 15;57(4):570-2 [9044826.001]
  • [Cites] Exp Physiol. 1997 Mar;82(2):361-8 [9129950.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2371-6 [9796967.001]
  • [Cites] Histopathology. 1989 Dec;15(6):653-8 [2606461.001]
  • (PMID = 17016487.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.1.1.45 / Thymidylate Synthase
  • [Other-IDs] NLM/ PMC2360543
  •  go-up   go-down


93. Tsiambas E, Karameris A, Dervenis C, Lazaris AC, Giannakou N, Gerontopoulos K, Patsouris E: HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis. JOP; 2006;7(3):283-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
  • CONTEXT: HER2/neu overexpression is observed in many cancers including pancreatic ductal adenocarcinoma.
  • Immunohistochemistry (clone TAB 250) and chromogenic (HER2/neu amplification Spot Light kit) in situ hybridization protocols were performed.
  • In contrast to breast cancer, protein overexpression does not predict this specific gene deregulation mechanism.
  • Furthermore, evaluation of HER2/neu protein expression based on digital image analysis and not only on conventional eye microscopy improves the accuracy and reliability of immunohistochemical estimation, although that does not demonstrate clinical significance and prognostic value in pancreatic ductal adenocarcinoma.
  • [MeSH-major] Carcinoma, Ductal, Breast / metabolism. Gene Amplification. Genes, erbB-2. Pancreatic Neoplasms / metabolism. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Aged. Aneuploidy. Chromosomes, Human, Pair 17. Female. Humans. Image Processing, Computer-Assisted. Immunohistochemistry / methods. In Situ Hybridization. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Reproducibility of Results. Staining and Labeling


94. Soini Y, Tommola S, Helin H, Martikainen P: Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of claudin expression associates with the diffuse subtype. Virchows Arch; 2006 Jan;448(1):52-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Membrane Proteins / biosynthesis. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology
  • [MeSH-minor] Apoptosis / physiology. Biomarkers, Tumor / analysis. Cadherins / biosynthesis. Cell Proliferation. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Ki-67 Antigen / biosynthesis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2003 Apr 3;22(13):2021-33 [12673207.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1745-54 [12000726.001]
  • [Cites] Breast Cancer Res. 2005;7(2):R296-305 [15743508.001]
  • [Cites] J Cell Biol. 1992 Apr;117(2):415-25 [1373144.001]
  • [Cites] J Am Soc Nephrol. 2002 Apr;13(4):875-86 [11912246.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6265-71 [14559813.001]
  • [Cites] J Cell Biol. 2000 Apr 3;149(1):13-6 [10747082.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Curr Opin Cell Biol. 2002 Oct;14(5):531-6 [12231346.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1620-6 [12459629.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1690-5 [8453643.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):678-84 [11522752.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7878-81 [11691807.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1531-6 [15619213.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1627-33 [15111309.001]
  • [Cites] J Cell Biol. 1988 Oct;107(4):1575-87 [3049625.001]
  • [Cites] J Cell Sci. 2004 May 15;117(Pt 12):2435-47 [15159449.001]
  • [Cites] Gastroenterology. 2001 Feb;120(2):411-22 [11159882.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Aug;279(2):G250-4 [10915631.001]
  • [Cites] Kidney Int. 2002 Aug;62(2):476-87 [12110008.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6281-7 [11103784.001]
  • [Cites] J Mol Cell Cardiol. 2005 Feb;38(2):323-32 [15698839.001]
  • (PMID = 16220299.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Ki-67 Antigen; 0 / Membrane Proteins
  •  go-up   go-down


95. Wasif N, Garreau J, Terando A, Kirsch D, Mund DF, Giuliano AE: MRI versus ultrasonography and mammography for preoperative assessment of breast cancer. Am Surg; 2009 Oct;75(10):970-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI versus ultrasonography and mammography for preoperative assessment of breast cancer.
  • Mammography and ultrasonography are traditional for preoperative estimation of breast cancer size; magnetic resonance imaging (MRI) is more recent but not as well studied.
  • We compared ultrasonography, mammography, and MRI for preoperative imaging of primary breast cancer presenting as a mass in patients treated at our center over a 2-year period.
  • Of the 61 breast cancers with all three imaging modalities performed, 52 were infiltrating ductal cancer, 5 were infiltrating lobular cancer, 2 were ductal carcinoma in situ, and 2 were other histologic types.
  • We conclude that MRI is more accurate than either ultrasonography or mammography for assessment of the size of primary breast cancer presenting as a mass.
  • [MeSH-major] Adenocarcinoma / diagnosis. Breast Neoplasms / diagnosis. Magnetic Resonance Imaging. Mammography. Ultrasonography, Mammary


96. Horn LC, Meinel A, Handzel R, Einenkel J: Histopathology of endometrial hyperplasia and endometrial carcinoma: an update. Ann Diagn Pathol; 2007 Aug;11(4):297-311
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnostic criteria of endometrial hyperplasia, endometrial in situ carcinoma, and of the different histologic types of EC, according to the most recent World Health Organization classification, are given in detail.
  • Endometrial pathologies in patients with breast cancer, receiving tamoxifen, and women affected by hereditary nonpolyposis colorectal cancer syndrome are described, including their pathogenetic aspects.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma in Situ / pathology. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / pathology. Pathology, Surgical / methods. Precancerous Conditions / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / classification. Adenocarcinoma, Clear Cell / pathology. Antineoplastic Agents, Hormonal / adverse effects. Carcinoma, Endometrioid / classification. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / classification. Cystadenocarcinoma, Serous / pathology. Endometrium / drug effects. Endometrium / pathology. Female. Humans. Specimen Handling / methods. Tamoxifen / adverse effects

  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Diagn Pathol. 2008 Jun;12(3):231-2; author reply 232-3 [18486902.001]
  • (PMID = 17630117.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  • [Number-of-references] 92
  •  go-up   go-down


97. Gu M, Ghafari S, Zhao M: Fluorescence in situ hybridization for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy specimens. Acta Cytol; 2005 Sep-Oct;49(5):471-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence in situ hybridization for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy specimens.
  • OBJECTIVE: To assess the usefulness of fluorescence in situ hybridization (FISH) for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy (FNAB) specimens.
  • RESULTS: FISH was performed on 41 surgical specimens of breast carcinoma.
  • Thirteen patients had prior FNABs that were positive for adenocarcinoma.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma / diagnosis. Gene Amplification / genetics. Genes, erbB-2 / genetics. In Situ Hybridization, Fluorescence / methods. Receptor, ErbB-2 / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334021.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


98. Farshid G, Pieterse S, King JM, Robinson J: Mucocele-like lesions of the breast: a benign cause for indeterminate or suspicious mammographic microcalcifications. Breast J; 2005 Jan-Feb;11(1):15-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucocele-like lesions of the breast: a benign cause for indeterminate or suspicious mammographic microcalcifications.
  • Most earlier reports of mucocele-like lesions (MLL) of the breast have dealt with symptomatic cases in premenopausal women or lesions found incidentally in breast biopsies performed for other reasons.
  • The diagnosis of this lesion has special challenges in the setting of mammographic screening for breast cancer because the imaging characteristics of MLL may mimic those of ductal carcinoma in situ (DCIS), while mucinous carcinoma enters the differential diagnosis on cytologic grounds.
  • Cases with MLL as the final histologic diagnosis in our database during January 1992-June 2000 are included.
  • Correlating the cytomorphology of mucinous lesions of the breast with their mammographic appearance may permit more precise preoperative diagnosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / epidemiology. Adenocarcinoma, Mucinous / radiography. Breast Neoplasms / epidemiology. Breast Neoplasms / radiography

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15647073.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Kobuya M: [Helical CT examination of the breast]. Nihon Hoshasen Gijutsu Gakkai Zasshi; 2005 Nov 20;61(11):1467-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Helical CT examination of the breast].
  • [MeSH-minor] Adenocarcinoma, Scirrhous / radiography. Breast Neoplasms / radiography. Carcinoma in Situ / radiography. Carcinoma, Ductal / radiography. Female. Humans

  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16317405.001).
  • [ISSN] 0369-4305
  • [Journal-full-title] Nihon Hōshasen Gijutsu Gakkai zasshi
  • [ISO-abbreviation] Nihon Hoshasen Gijutsu Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 30
  •  go-up   go-down


100. Levine P, Simsir A, Cangiarella J: Management issues in breast lesions diagnosed by fine-needle aspiration and percutaneous core breast biopsy. Am J Clin Pathol; 2006 Jun;125 Suppl:S124-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management issues in breast lesions diagnosed by fine-needle aspiration and percutaneous core breast biopsy.
  • The use offine-needle aspiration biopsy or percutaneous core needle biopsy to diagnose breast lesions has increased during the past few decades.
  • Although the benefits of these procedures are well known, controversies remain about the management of certain categories of breast lesions detected by these methods.
  • This article discusses the management issues in categories of breast lesions, including papillary lesions, atypical lobular hyperplasia and lobular carcinoma in situ, and mucinous lesions diagnosed by the preoperative techniques of aspiration or core biopsy.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Biopsy, Fine-Needle / methods. Breast / pathology. Breast Neoplasms / pathology. Carcinoma, Lobular / pathology. Carcinoma, Papillary / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16830962.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 139
  •  go-up   go-down






Advertisement